Table of Contents



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549


FORM 10-Q


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SeptemberJune 30, 20222023

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission File Number: 001-38238


Venus Concept Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware

06-1681204

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

235 Yorkland Blvd., Suite 900

Toronto, Ontario M2J 4Y8

(877) 848-8430

(Address including zip code, and telephone number including area code, of registrants principal executive offices)

 


 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

VERO

 

The Nasdaq GlobalCapital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes   ☒    No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

    

Non-accelerated filer

Smaller reporting company

    
  

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

 

As of November 8, 2022August 9, 2023 the registrant had 67,584,5735,526,481 shares of common stock, $0.0001 par value per share, outstanding.



 

 

 

 

 

Table of Contents

 

 

 

Page

Part I.

Financial Information

2

Item 1.

Condensed Consolidated Financial Statements (unaudited)

2

 

Condensed Consolidated Balance Sheets

2

 

Condensed Consolidated Statements of Operations

3

 

Condensed Consolidated Statements of Comprehensive Loss

4

 

Condensed Consolidated Statements of Stockholders’ Equity

5

 

Condensed Consolidated Statements of Cash Flows

6

 

Notes to the Condensed Consolidated Financial Statements

7

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

3325

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

5745

Item 4.

Controls and Procedures

5745

PART II.

Other Information

5846

Item 1.

Legal Proceedings

5846

Item 1A.

Risk Factors

5846

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

5947

Item 3.

Defaults Upon Senior Securities

6048

Item 4.

Mine Safety Disclosures

6048

Item 5.

Other Information

6048

Item 6.

Exhibits

6048

Signatures

6149

 

i

 

 

PART I

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

VENUS CONCEPT INC.

 

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

ASSETS

        

CURRENT ASSETS:

  

Cash and cash equivalents

 $6,777 $30,876  $6,122 $11,569 

Accounts receivable, net of allowance of $13,102 and $11,997 as of September 30, 2022, and December 31, 2021, respectively

 40,876 46,918 

Accounts receivable, net of allowance of $13,233 and $13,619 as of June 30, 2023, and December 31, 2022, respectively

 37,520 37,262 

Inventories

 24,241 20,543  22,936 23,906 

Prepaid expenses

 1,912 2,737  1,481 1,688 

Advances to suppliers

 3,605 2,162  5,749 5,881 

Other current assets

 3,351 3,758  1,984 3,702 

Total current assets

 80,762  106,994   75,792   84,008 

LONG-TERM ASSETS:

  

Long-term receivables

 23,253 27,710 

Long-term receivables, net

 12,082 20,044 

Deferred tax assets

 912 284  876 947 

Severance pay funds

 724 817  586 741 

Property and equipment, net

 2,180 2,669  1,640 1,857 

Operating right-of-use assets, net

 4,983 5,862 

Intangible assets

  12,795  15,393   10,197  11,919 

Total long-term assets

  39,864   46,873   30,364   41,370 

TOTAL ASSETS

 $120,626  $153,867  $106,156  $125,378 

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

CURRENT LIABILITIES:

  

Trade payables

 $6,093 $4,913  $8,293 $8,033 

Accrued expenses and other current liabilities

 17,335 19,512  13,063 16,667 

Current portion of long-term debt

 7,735 7,735 

Income taxes payable

 827 294  434 117 

Unearned interest income

 2,575 2,678  1,915 2,397 

Warranty accrual

 1,147 1,245  880 1,074 

Deferred revenues

 1,535 2,030  1,050 1,765 

Current portion of government assistance loans

    543 

Operating lease liabilities

  1,571  1,807 

Total current liabilities

 29,512  31,215  34,941  39,595 

LONG-TERM LIABILITIES:

  

Long-term debt

 77,616 77,325  70,683 70,003 

Income tax payable

 592 563  385 374 

Deferred tax liabilities

 6  

Accrued severance pay

 845 911  696 867 

Deferred tax liabilities

 54 46 

Unearned interest income

 1,355 1,355 

Unearned interest revenue

 552 957 

Warranty accrual

 426 508  377 408 

Operating lease liabilities

 3,666 4,221 

Other long-term liabilities

  213  348   392  215 

Total long-term liabilities

  81,101   81,056   76,757   77,045 

TOTAL LIABILITIES

  110,613   112,271   111,698   116,640 

Commitments and Contingencies (Note 8)

       

STOCKHOLDERS’ EQUITY:

 

Common Stock, $0.0001 par value: 300,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 65,584,573 and 63,982,580 issued and outstanding as of September 30, 2022, and December 31, 2021, respectively

 27 27 

Commitments and Contingencies (Note 9)

       

STOCKHOLDERS’ EQUITY (Note 14):

 

Common Stock, $0.0001 par value: 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 5,526,481 and 5,161,374 issued and outstanding as of June 30, 2023, and December 31, 2022, respectively

 30 29 

Additional paid-in capital

 223,506 221,321  235,467 232,169 

Accumulated deficit

  (214,188)  (180,405)  (241,719)  (224,105)

TOTAL STOCKHOLDERS’ EQUITY

 9,345  40,943  (6,222) 8,093 

Non-controlling interests

  668  653  680 645 
  10,013   41,596   (5,542)  8,738 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 $120,626  $153,867  $106,156  $125,378 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

2

 

 

VENUS CONCEPT INC.

 

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Revenue

                    

Leases

 $7,193  $12,634  $29,490  $33,958  $4,311  $11,874  $10,072  $22,297 

Products and services

  14,346   11,929   45,721   39,030   15,764   15,392   30,534   31,375 
 21,539  24,563  75,211  72,988  20,075  27,266  40,606  53,672 

Cost of goods sold

 

Cost of goods sold:

         

Leases

 2,608 2,938 8,069 7,444  721  2,761  2,450  5,461 

Products and services

  5,558  4,319  16,960  14,287   5,134   5,459   10,237   11,402 
  8,166   7,257   25,029   21,731   5,855   8,220   12,687   16,863 

Gross profit

  13,373   17,306   50,182   51,257   14,220   19,046   27,919   36,809 

Operating expenses:

          

Sales and marketing

 8,094  8,775  27,484  26,743 

Selling and marketing

 8,380  10,523  16,412  21,607 

General and administrative

 14,128  11,990  41,471  31,983  9,633  12,937  20,818  24,409 

Research and development

 2,576  1,930  7,214  6,005   1,965   2,712   4,602   5,355 

Gain on forgiveness of government assistance loans

        (2,775)

Total operating expenses

  24,798   22,695   76,169   61,956   19,978   26,172   41,832   51,371 

Loss from operations

  (11,425)  (5,389)  (25,987)  (10,699)  (5,758)  (7,126)  (13,913)  (14,562)

Other expenses:

          

Foreign exchange loss

 2,014  1,645  4,389  2,489 

Foreign exchange loss (gain)

 (178) 2,370  (530) 2,375 

Finance expenses

  1,219   1,000   3,176   4,046  1,553  1,034  3,061  1,957 

Loss on disposal of subsidiaries

    188    188 

(Gain) loss on disposal of subsidiaries

  (1)  -   76   - 

Loss before income taxes

 (14,658) (8,222) (33,552) (17,422) (7,132) (10,530) (16,520) (18,894)

Income tax (benefit) expense

  (162)  616   92   609   189   (18)  424   254 

Net loss

  (14,496)  (8,838)  (33,644)  (18,031)  (7,321)  (10,512)  (16,944)  (19,148)

Net loss attributable to stockholders of the Company

  (14,605)  (9,798)  (33,783)  (18,680)  (7,409)  (10,559)  (17,066)  (19,178)

Net income attributable to non-controlling interest

  109   960   139   649   88   47   122   30 
          

Net loss per share:

          

Basic

 $(0.22) $(0.18) $(0.52) $(0.35) $(1.35) $(2.47) $(3.19) $(4.49)

Diluted

 $(0.22) $(0.18) $(0.52) $(0.35) $(1.35) $(2.47) $(3.19) $(4.49)

Weighted-average number of shares used in per share calculation:

          

Basic

  65,255  54,145  64,462  53,994   5,471   4,276   5,355   4,271 

Diluted

  65,255   54,145   64,462   53,994   5,471   4,276   5,355   4,271 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

VENUS CONCEPT INC.

 

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(in thousands)

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Net loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

Loss attributable to stockholders of the Company

 (14,605) (9,798) (33,783) (18,680) (7,409) (10,559) (17,066) (19,178)

Income attributable to non-controlling interest

  109   960   139   649   88   47   122   30 

Comprehensive loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

 

VENUS CONCEPT INC.

 

Condensed Consolidated Statements of Stockholders Equity

(Unaudited)

(in thousands, except share data)

 

 

Series A Preferred

 

Series A Preferred

  

Common Stock

 

Additional Paid-

 

Accumulated

 

Non- controlling

 

Total Stockholders’

  

2022 Private Placement

 

2023 Multi-Tranche Private Placement

  

Common Stock

 

Additional Paid-

 

Accumulated

 

Non- controlling

 

Total Stockholders’

 
 

Shares

  

Amount

  

Shares

  

Amount

  

in-Capital

  

Deficit

  

Interest

  

Equity

  

Shares*

  

Shares*

  

Shares

  

Amount

  

in-Capital

  

Deficit

  

Interest

  

Equity

 

Balance — January 1, 2022

 3,790,755  $   63,982,580  $27  $221,321  $(180,405) $653  $41,596 

Options exercised

      16,464    23      23 

Net loss — the Company

            (8,619)   (8,619)

Net loss — non-controlling interest

              (17) (17)

Stock-based compensation

              443         443 

Balance — March 31, 2022

  3,790,755  $   63,999,044   27   221,787   (189,024)  636   33,426 

Balance — January 1, 2023

 3,185,000      5,161,374  $29  $232,169  $(224,105) $645  $8,738 

Restricted share units vested

     22,000     - 

Issuance of common stock

     224,378 1 744   745 

Adoption of ASC 326

        (548)  (548)

Net loss — the Company

        (10,559)  (10,559)            (9,657)   (9,657)

Net income — non-controlling interest

         47 47               34  34 

Equity issuance

     400,000  48   48 

Stock-based compensation

       558   558               481         481 

Dividends from subsidiaries

               (124)  (124)

Balance — June 30, 2022

  3,790,755  $   64,399,044   27   222,393   (199,583)  559   23,396 

Balance — March 31, 2023

  3,185,000      5,407,752  $30  $233,394  $(234,310) $679  $(207)

2023 Private Placement shares, net of costs

  280,899     1,206   1,206 

Beneficial conversion feature

       427   427 

Issuance of common stock

     118,729  71   71 

Net loss — the Company

        (14,605)  (14,605)        (7,409)  (7,409)

Net income — non-controlling interest

         109 109          88 88 

Equity issuance

     1,185,529  562   562 

Dividends from subsidiaries

         (87) (87)

Stock-based compensation

       551   551            369      369 

Dividends from subsidiaries

                  

Balance — September 30, 2022

  3,790,755 $   65,584,573  27  223,506  (214,188)  668  10,013 

Balance — June 30, 2023

  3,185,000  280,899   5,526,481 $30 $235,467 $(241,719) $680 $(5,542)

 

 

Series A Preferred

 

Series A Preferred

  

Common Stock

 

Additional Paid-

 

Accumulated

 

Non- controlling

 

Total Stockholders’

  

Series A Preferred

  

Common Stock

 

Additional Paid-

 

Accumulated

 

Non- controlling

 

Total Stockholders’

 
 

Shares

  

Amount

  

Shares

  

Amount

  

in-Capital

  

Deficit

  

Interest

  

Equity

  

Shares*

  

Shares

  

Amount

  

in-Capital

  

Deficit

  

Interest

  

Equity

 

Balance — January 1, 2021

   $   53,551,126  $26  $201,598  $(157,392) $(471) $43,761 

December 2020 Public Offering warrants exercise

      361,200    903      903 

Balance — January 1, 2022

 252,717  4,265,506  $27  $221,321  $(180,405) $653  $41,596 

Options exercised

      157,304    212      212    1,098    23      23 

Net loss — the Company

            (9,259)   (9,259)         (8,619)   (8,619)

Net loss — non-controlling interest

              (176) (176)           (17) (17)

Stock-based compensation

              508         508            443         443 

Balance — March 31, 2021

    $   54,069,630   26   203,221   (166,651)  (647)  35,949 

Options exercised

      72,192    98     98 

Net income — the Company

            377    377 

Balance — March 31, 2022

  252,717   4,266,604  $27  $221,787  $(189,024) $636  $33,426 

Net loss — the Company

         (10,559)   (10,559)

Net loss — non-controlling interest

              (135) (135)           47  47 

Issuance of common stock

   26,667    48      48 

Stock-based compensation

              558         558        558      558 

Balance — June 30, 2021

    $   54,141,822   26   203,877   (166,274)  (782)  36,847 

Options exercised

     16,147    22     22 

Net loss — the Company

        (9,798)  (9,798)

Net income — non-controlling interest

         960 960 

Acquisition of non-controlling interest

       (341)  341  

Disposal of subsidiary

         204 204 

Stock-based compensation

           536      536 

Balance — September 30, 2021

   $   54,157,969  26  204,094  (176,072)  723  28,771 

Dividends from subsidiaries

                 (124)  (124)

Balance — June 30, 2022

  252,717   4,293,271  $27  $222,393  $(199,583) $559  $23,396 

Note: Share amounts have been retroactively adjusted to reflect the impact of a 1-for-15 reverse stock split effected in May 2023, as discussed in Note 2.

*: Amounts associated with Private Placement and Preferred shares round to $nil.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

VENUS CONCEPT INC.

 

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

 

Nine Months Ended September 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2023

  

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net loss

 $(33,644) $(18,031) $(16,944) $(19,148)

Adjustments to reconcile net loss to net cash used in operating activities:

  

Depreciation and amortization

 3,293  3,756  2,032 2,212 

Stock-based compensation

 1,552  1,602  850 1,001 

Provision (recovery) for bad debt

 5,912  (628)

Provision for expected credit losses

 977 3,521 

Provision for inventory obsolescence

 1,753  1,107  674 862 

Finance expenses and accretion

 291  981  680 182 

Deferred tax recovery

 (620) (666)

Loss on disposal of subsidiary

   188 

Gain on forgiveness of government assistance loans

   (2,775)

Deferred tax expense (recovery)

 78 (283)

Loss on sale of subsidiary

 76 - 

Loss on disposal of property and equipment

 82    - 31 

Changes in operating assets and liabilities:

  

Accounts receivable short and long-term

 4,493  3,468 

Accounts receivable short-term and long-term

 6,153 (2,492)

Inventories

 (5,451) (4,373) 297 (2,682)

Prepaid expenses

 825  (112) 207 568 

Advances to suppliers

 (1,443) (142) 132 (3,797)

Other current assets

 407  909  1,642 (115)

Operating right-of-use assets, net

 879 6,057 

Other long-term assets

 327  (102) (268) (79)

Trade payables

 1,180  (1,573) 259 2,361 

Accrued expenses and other current liabilities

 (2,237) (3,135) (4,185) (1,969)

Current operating lease liabilities

 (236) (1,764)

Severance pay funds

 93  (58) 154 2 

Unearned interest income

 (103) 127  (887) 284 

Long-term operating lease liabilities

 (555) (4,293)

Other long-term liabilities

  (283)  87   (25)  (172)

Net cash used in operating activities

  (23,573)  (19,370)  (8,010)  (19,713)

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchases of property and equipment

 (297) (194)  (92)  (251)

Cash received from sale of subsidiary, net of cash relinquished

     (40)

Net cash used in investing activities

  (297)  (234)  (92)  (251)

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Proceeds from issuance of common stock, net of costs

 415   

Exercises of 2020 December Public Offering Warrants

   903 

Payment of earn-out liability

   (147)

2023 Multi-Tranche Private Placement, net of costs of $367

 1,633  

Proceeds from exercise of options

  23 

Proceeds from issuance of common stock

 1,109 272 

Repayment of government assistance loans

 (543)    (543)

Proceeds from exercise of options

 23  332 

Dividends from subsidiaries paid to non-controlling interest

  (124)     (87)  (124)

Net cash (used in) provided by financing activities

  (229)  1,088   2,655   (372)

NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

 (24,099) (18,516) (5,447) (20,336)

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period

  30,876   34,380   11,569   30,876 

CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period

 $6,777  $15,864  $6,122  $10,540 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

        

Cash paid for income taxes

 $152  $120  $18 $224 

Cash paid for interest

 $2,885  $2,852  $2,381 $1,775 

FINANCING INFORMATION:

    

Common stock issuance costs

 $438    

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

VENUS CONCEPT INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

(in thousands, unless otherwise noted, except share and per share data)

 

 

1. NATURE OF OPERATIONS

 

Venus Concept Inc. is a global medical technology company that develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company’sCompany's systems have been designed on cost-effective, proprietary and flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company was incorporated in the state of Delaware on November 22, 2002. In these notes to the unaudited condensed consolidated financial statements, the “Company” and “Venus Concept”, refer to Venus Concept Inc. and its subsidiaries on a consolidated basis.

 

Going Concern

 

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

The Company has had recurring net operating losses and negative cash flows from operations. As of SeptemberJune 30, 20222023 and December 31, 20212022, the Company had an accumulated deficit of $214,188$241,719 and $180,405, respectively. The$224,105, respectively, though, the Company was in compliance with all required covenants as of SeptemberJune 30, 20222023, and December 31, 20212022. The Company’s recurring losses from operations and negative cash flows raise substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date that the unaudited condensed consolidated financial statements are issued. As of September 30, 2022, and for the nine months then ended management believes the impact of Covid-19 on our business has largely subsided, but we continue to closely monitor all Covid-19 developments including its impact on our customers, employees, suppliers, vendors, business partners, and distribution channels. In addition, theThe global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases toincreasing inflation rates, rising interest rates, foreign currency impacts, declines in consumer confidence, and declines in economic growth. All these factors point to uncertainty about economic stability, and the severity and duration of these conditions on our business cannot be predicted, and the Company cannot assure that it will remain in compliance with the financial covenants contained within its credit facilities. 

 

In order to continue its operations, the Company must achieve profitable operations and/or obtain additional equity or debt financing. Until the Company achieves profitability, management plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock. On June 16, 2020, the Companywe entered into a purchase agreement (the "Equity Purchase Agreement") with Lincoln Park Capital Fund LLC ("Lincoln Park"), which provided that, upon the terms and subject to the conditions and limitations set forth therein, the Company may sell to Lincoln Park up to $31,000 worth$31.0 million of shares of itsour common stock from timepursuant to time overour shelf registration statement. During the two-year term of the agreement. Any shares of common stockyear ended December 31, 2022 and until its expiry in July 2022, we sold to Lincoln Park will be sold at a purchase price that is based on the prevailing prices0.02 million shares of theour common stock at the time of each sale. During the nine months ended September 30,2022, the Companyand raised net cash proceeds of$272 $0.3 million under the Equity Purchase Agreement as described below. The Equity Purchase Agreement expired on July 1, 2022. Agreement. On July 12, 2022, the Companywe entered into a subsequent purchase agreement (the "2022 LPC Purchase Agreement”Agreement") with Lincoln Park, which will enhance our balance sheet and financial condition to support our future growth initiatives. As part of the details of which are described Note 142022 below. In December 2021, the CompanyLPC Purchase Agreement, we issued and sold to investors 9,808,418Lincoln Park 0.05 million shares of our common stock as a commitment fee for entering into the 2022 LPC Purchase Agreement with the total value of $0.3 million. Since commencement of the 2022 LPC Purchase Agreement through June 30, 2023, the Company issued an additional 0.78 million shares of common stock par value $0.0001 per share, and 3,790,755 sharesto Lincoln Park at an average price of the convertible preferred stock, par value $0.0001$3.97 per share, for a total value of $3.1 million. Additionally, the totalCompany completed private placement offerings in 2022 and 2023 which generated gross proceeds of $16,999 (see “The 2021 Private Placement” in$8.7 million. Refer to Note 14). In February 2021, several investors exercised an aggregate of 361,200 December 2020 Public Offering Warrants at the exercise price of $2.50 per share. The total proceeds received by the Company from the December 2020 Public Offering Warrants exercises were $903. “Stockholders Equity” for additional details. Until the Company generates revenue at a level to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows from operating activities.

 

Given the economic uncertainty in U.S. and international markets, the Company cannot anticipate the extent to which the current economic turmoil and financial market conditions will continue to adversely impact the Company’s business and the Company may need additional capital to fund its future operations and to access the capital markets sooner than planned. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, it may be compelled to reduce the scope of its operations and planned capital expenditures or sell certain assets, including intellectual property assets. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the uncertainty. Such adjustments could be material.

 

Operational ReviewThe accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of Subsidiaries

Duringassets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the unaudited condensed consolidated financial statements do threenot include any adjustments relating to the recoverability and nine months ended September 30, 2022, the Boardclassification of Directorsrecorded asset amounts or amounts and classification of liabilities that might be necessary should the Company (the "Board") made several strategic decisionsbe unable to dissolve itself of underperforming direct sales officescontinue in the countries which were not anticipated to produce sustainable results. As a part of this initiative, the Company has enacted a plan to dissolve its equity interests in Venus Concept Sucursal Colombia ("Venus Colombia"), a branch office of Venus Concept Canada Corp ("Venus Canada"), Venus Concept France SAS ("Venus France"), and Venus Concept Argentina SA ("Venus Argentina"). No divestitures have occurred during the three and nine months ended September 30, 2022 and no severance costs are expected to be incurred in association with the planned divestiture of Venus Colombia, Venus France, or Venus Argentina. The Company did recognize employee severance and retention cost associated with Venus Concept SL ("Venus Spain") totaling $126 during three and nine months ended September 30, 2022. The Company is also assessing lease exit costs associated with the planned divestiture of Venus France, which are expected to be immaterial. These disposals will not constitute a strategic shift that will have a major effect on the Company’s operations and financial results, therefore the results of operations and net assets of these subsidiaries are not reported as discontinued operations or held for sale, respectively, under the guidance of Accounting Standards Codification (“ASC”) 205-20-45.existence.

 

7

 
 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of Venus Concept Inc. have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 20212022, filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2022.27, 2023. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the ninesix months ended SeptemberJune 30, 20222023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.2023. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K.

 

In the Form 10-Q for the period ended March 31, 2021, filed with the SEC on May 17, 2021, in the Form 10-Q for the period ended June 30, 2021, filed with the SEC on August 17, 2021, in the form 10-Q for the period ended September 30, 2021, filed with the SEC on November 12, 2021 and in the Form 10-K for the year ended December 31, 2021, filed with the SEC on March 28, 2022, the revenue by geographic location, which is based on the product shipped to location, was presented incorrectly (see below). The Company corrected the presentation in the accompanying unaudited condensed consolidated financial statements for the periods presented (see Note 16).

  

Reclassification Adjustment

 
  Three Months Ended  Year Ended 
  

March 31, 2021

  

June 30, 2021

  

September 30, 2021

  

December 31, 2021

  

December 31, 2021

 

United States

 $(362) $(615) $(703) $(440) $(2,120)

International

  362   615   703   440   2,120 

Total revenue

 $  $  $  $  $ 

The preparation of these unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company as of SeptemberJune 30, 20222023 and through the date of this report filing. The accounting matters assessed included, but were not limited to, the allowance for doubtful accountsexpected credit losses and the carrying value of intangible and long-lived assets.

At the annual and special meeting of the Company’s shareholders held on May 10, 2023, the Company’s shareholders granted the Company’s Board of Directors discretionary authority to implement a consolidation of the issued and outstanding common shares of the Company (a "Reverse Stock Split") and to fix the specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-fifteen (1-for-15) consolidation. On May 11, 2023, the Company filed an amendment to the Company’s Certificate of Incorporation to implement the Reverse Stock Split based on a one-for-fifteen (1-for-15) consolidation ratio. The Company’s common shares began trading on the Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trade symbol “VERO” at the opening of the market on May 12, 2023. In accordance with U.S. GAAP, the change has been applied retroactively.

 

Amounts reported in thousands within this report are computed based on the amounts in U.S. dollars. As a result, the sum of the components reported in thousands may not equal the total amount reported in thousands due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

 

8

Accounting Policies

 

The accounting policies the Company follows are set forth in the Company’s audited consolidated financial statements for fiscal year 20212022. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. There have been no material changes to these accounting policies.

 

JOBS Act Accounting Election

The Company is an emerging growth company, within the meaning of the 1933 Act, as modified by the Jumpstart Our Business Startups Act (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Adopted Accounting Standards 

 

In November 2021,June 2016, the FASBFinancial Accounting Standards Board (“FASB”) issued ASUAccounting Standards Board Update (“ASU”) No.20212016-10,13, Government AssistanceFinancial Instruments – Credit Losses (Topic 832326). The authoritative guidance intended to provide consistent and transparent disclosures around government assistance by requiring disclosuresMeasurement of the type of government assistance, our accounting for the government assistance and the effectCredit Losses on our financial statements. This guidance was effective for the Company for the year ended December 31, 2021. See Note 12 for more details regarding government assistance. 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260): Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718)Financial Instruments, and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopicalso issued subsequent amendments to the initial guidance: ASU 8152018-4019,)”, which clarifies and reduces diversity in an issuer’s accounting for a modification or an exchange of a freestanding equity-classified written call option that remains equity being classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. This was effective for fiscal years beginning after December 15, 2021, and interim periods within those years. The adoption of the guidance did not have a material impact on the Company's unaudited condensed consolidated financial statements.  

In December 2019, the FASB issued ASU 2019-1204, – Income Taxes (TopicASU 7402019): Simplifying-05, ASU 2019-10, ASU 2019-11, and ASU 2020-02, which replace the Accounting for Income Taxes,existing incurred loss impairment model with an authoritativeexpected credit loss model and require a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas. It is effective from thewas adopted as of firstJanuary 1, 2023.  quarterThe Company recognized a charge of fiscal year 2022, with early adoption permitted in any interim period. The amendments have differing adoption methods including retrospectively, prospectively and/or modified retrospective basis through a cumulative-effect adjustment$0.5 million to opening retained earnings as a result of the beginning of the fiscal year of adoption, depending on the specific change. The adoption of the guidance did not have a material impact on the Company’s unaudited condensed consolidated financial statements.adoption.

 

Recently Issued Accounting Standards Not Yet Adopted

In October 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update ("ASU") No.2021-08, Business Combinations (Topic 805),Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an entity (acquirer) to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company is currently evaluating the impact the standard will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”): Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require usthe Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for the Company on January 1, 2024, with early adoption permitted. ASU No. 2020-06 can be adopted on either a fully retrospective or modified retrospective basis. The Company is currently assessing the impact of applying this guidance as well as when to adopt this guidance.

 

In April 2020, the FASB issued a Staff Question-and-Answer Document (Q&A): ASC Topic 842 and ASC Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic, that focuses on the application of the lease guidance for lease concessions related solely to the effects of COVID-19. The FASB issued the guidelines to reduce the burden and complexity for companies to account for such lease concessions (e.g., rent abatements or other economic incentives) under current lease accounting rules due to COVID-19 by providing certain practical expedients that can be used. This guidance can be applied immediately.

98

 

In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04 - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASC Topic 848). This authoritative guidance provides optional relief for companies preparing for the discontinuation of interest rates such as LIBOR, which was phased out at the end of calendar 2021, and applies to lease contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that have LIBOR as the benchmark rate. This guidance can be applied for a limited time, as of the beginning of the interim period that includes March 12, 2020 or any date thereafter, through December 31, 2022. The guidance may no longer be applied after December 31, 2022. In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR, or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC Topic 848. The adoption of the guidance did not have a material impact on the Company’s unaudited condensed consolidated financial statements.

In February 2020, the FASB issued authoritative guidance (ASU 2020-02 – Financial Instruments – Credit Losses (Topic 326) and Leases (Topic 842)) that amends and clarifies Topic 326 and Topic 842. For Topic 326, the codification was updated to include the SEC staff interpretations associated with registrants engaged in lending activities. ASC Topic 326 is effective for annual periods beginning after January 1, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of applying this guidance on its financial instruments, such as accounts receivable.

 

3. NET LOSS PER SHARE

 

Net Loss Per Share

 

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock warrants and stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

 

10

The following table sets forth the computation of basic and diluted net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data):

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Numerator:

          

Net loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

Net loss allocated to stockholders of the Company

 $(14,605) $(9,798) $(33,783) $(18,680) $(7,409) $(10,559) $(17,066) $(19,178)

Denominator:

          

Weighted-average shares of common stock outstanding used in computing net loss per share, basic

  65,255  54,145  64,462  53,994  5,471  4,276  5,355  4,271 

Weighted-average shares of common stock outstanding used in computing net loss per share, diluted

 65,255  54,145  64,462  53,994   5,471   4,276   5,355   4,271 

Net loss per share:

          

Basic

 $(0.22) $(0.18) $(0.52) $(0.35) $(1.35) $(2.47) $(3.19) $(4.49)

Diluted

 $(0.22) $(0.18) $(0.52) $(0.35) $(1.35) $(2.47) $(3.19) $(4.49)

 

The following potentially dilutive securities

Due to the net loss, all the outstanding shares of common stock equivalents were excluded from the computationcalculation of the diluted net loss per share attributable to common stockholders for the periods presentedquarters ended June 30, 2023 and 2022 because their effectincluding them would have been antidilutive: 

 

 

September 30, 2022

  

September 30, 2021

  

June 30, 2023

  

June 30, 2022

 

Options to purchase common stock and restricted stock units ("RSUs")

 7,483,514  5,695,900  1,019,837 488,255 

Preferred stock

 3,790,755 -  2,872,518 252,717 

Shares reserved for convertible notes

 8,213,880 8,213,880  558,666 547,593 

Warrants for common stock

  15,928,867   15,928,867   1,061,930   1,061,930 

Total potential dilutive shares

  35,417,016   29,838,647   5,512,951   2,350,495 

 

 

4. FAIR VALUE MEASUREMENTS

 

Financial assets and financial liabilities are initially recognized at fair value when the Company becomes a party to the contractual provisions of the financial instrument. Subsequently, all financial instruments are measured at amortized cost using the effective interest method, except for GIC which is at fair value.method.

 

The financial instruments of the Company consist of cash and cash equivalents, restricted cash, accounts receivable, long-term receivables, lines of credit, trade payables, government assistance loans, accrued expenses and other current liabilities, other long-term liabilities and long-term debt. In view of their nature, the fair value of these financial instruments approximates their carrying amounts.

 

The Company measures the fair value of its financial assets and financial liabilities using the fair value hierarchy. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

Level 1 – Quoted prices in active markets for identical assets or liabilities.

 

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

11

Guaranteed investment certificates (“GIC”) are classified within Level 2 as the Company uses alternative pricing sources and models utilizing market observable inputs for valuation. The following tables set forth the fair value of the Company’s Level 1, Level 2 and Level 3 financial assets and liabilities within the fair value hierarchy: 

 

 

Fair Value Measurements as of September 30, 2022

  

Fair Value Measurements as of June 30, 2023

 
 

Quoted Prices in Active Markets using Identical Assets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

  

Total

  

Quoted Prices in Active Markets using Identical Assets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

  

Total

 

Assets

          

GIC

 $  $60  $  $60 

Guaranteed Investment Certificates

 $ $62 $ $62 

Total assets

 $  $60  $  $60  $  $62  $  $62 

 

  

Fair Value Measurements as of December 31, 2021

 
  

Quoted Prices in Active Markets using Identical Assets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

  

Total

 

Assets

                

GIC

 $  $64  $  $64 

Total assets

 $  $64  $  $64 

  

Fair Value Measurements as of December 31, 2022

 
  

Quoted Prices in Active Markets using Identical Assets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

  

Total

 

Assets

                

Guaranteed Investment Certificates

 $  $59  $  $59 

Total assets

 $  $59  $  $59 

 

129

 
 

5. ACCOUNTS RECEIVABLE

 

The Company’s products may be sold under subscription agreements with unencumbered title passing to the customer at the end of the lease term, which is generally 36 months. These arrangements are considered to be sales-type leases, where the present value of all cash flows to be received under the agreement is recognized upon shipment to the customer as lease revenue.

 

A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company's unaudited condensed consolidated balance sheets. The Company's financing receivables, consisting of sales-type leases, totaled $45,497$28,259 and $53,887$40,377 as of SeptemberJune 30, 20222023 and December 31, 20212022, respectively, and are included in accounts receivable and long-term receivables on the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of an obligor at lease inception and monitors credit quality over the term of the underlying transactions.

 

The Company performed an assessment of the allowance for doubtful accountsexpected credit losses as of SeptemberJune 30, 20222023 and December 31, 20212022. Based upon such assessment, the Company recorded an allowance for doubtful accountsexpected credit losses totaling $13,102$13,233 and $11,997$13,619 as of SeptemberJune 30, 20222023, and December 31, 20212022, respectively. The balance as of June 30, 2023 includes $0.5 million due to the adoption of revised guidance of Financial Instruments – Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments.

 

A summary of the Company’s accounts receivables is presented below:

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Gross accounts receivable

 $77,231  $86,625  $62,835  $70,925 

Unearned income

 (3,930) (4,033) (2,467) (3,354)

Allowance for doubtful accounts

  (13,102)  (11,997)

Allowance for expected credit losses

  (13,233)  (13,619)
 $60,199  $70,595  $47,135  $53,952 

Reported as:

  

Current trade receivables

 $40,876  $46,918  $37,520  $37,262 

Current unearned interest income

 (2,575) (2,678) (1,915) (2,397)

Long-term trade receivables

 23,253  27,710  12,082  20,044 

Long-term unearned interest income

  (1,355)  (1,355)  (552)  (957)
 $60,199  $70,595  $47,135  $53,952 

 

Current subscription agreements are reported as part of accounts receivable. The following are the contractual commitments, net of allowance for doubtful accounts,expected credit losses, to be received by the Company over the next 5 years:

 

      

September 30,

 
  

Total

  

2022

  

2023

  

2024

  

2025

  

2026

 

Current financing receivables, net of allowance of $6,293

 $22,500  $22,500  $  $  $  $ 

Long-term financing receivables, net of allowance of $779

  22,997      17,499   5,463   35    
  $45,497  $22,500  $17,499  $5,463  $35  $ 
      

June 30,

 
  

Total

  

2023

  

2024

  

2025

  

2026

  

2027

 

Current financing receivables, net of allowance of $5,475

 $16,177  $16,177  $  $  $  $ 

Long-term financing receivables, net of allowance of $536

 $12,082  $  $10,334  $1,734  $14  $ 
  $28,259  $16,177  $10,334  $1,734  $14  $ 

 

Accounts receivable do not bear interest and are typically not collateralized. The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for doubtful accounts.expected credit losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts receivable are presented net of an allowance for doubtful accounts.expected credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Actual losses may differ from the Company’s estimates and could be material to its unaudited condensed consolidated financial position, results of operations and cash flows.

 

The allowance for expected credit losses consisted of the following activity:

Balance at January 1, 2022

$11,997 

Write-offs

 (5,715)

Provision

 7,337 

Balance at December 31, 2022

$13,619 

Write-offs

 (30)

Provision

 618 

Balance at March 31, 2023

$14,207 

Write-offs

 (1,332)

Provision

 358 

Balance at June 30, 2023

$13,233 

1310

 

The allowance for doubtful accounts consisted of the following activity:

Balance at January 1, 2021

 $18,490 

Write-offs

  (6,230)

Recovery

  (263)

Balance at December 31, 2021

  11,997 

Write-offs

  (259)

Provision

  1,004 

Balance at March 31, 2022

  12,742 

Write-offs

  (1,159)

Provision

  2,517 

Balance at June 30, 2022

  14,100 

Write-offs

  (3,389)

Provision

  2,391 

Balance at September 30, 2022

 $13,102 

 

6. SELECT BALANCE SHEET AND STATEMENT OF OPERATIONS INFORMATION

 

Inventory

 

Inventory consists of the following:

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Raw materials

 $2,275 $2,368  $2,211 $2,478 

Work-in-progress

 1,268 1,649  1,596 2,112 

Finished goods

  20,698  16,526   19,129  19,316 

Total inventory

 $24,241  $20,543  $22,936  $23,906 

 

Additions to inventory are primarily comprised of newly produced units and applicators, refurbishment cost from demonstration units and used equipment which were reacquired during the period from upgraded sales. The Company expensed $7,696$5,124 and $23,437$11,956 in cost of goods sold in the three and ninesix months ended SeptemberJune 30, 2023, 30,2022, respectively ($6,584respectively. The Company expensed $7,731 and $19,150$15,231 in cost of goods sold in the three and ninesix months ended SeptemberJune 30, 2022, 30,2021, respectively). respectively. The balance of cost of goods sold represents the sale of applicators, parts and warranties.

 

The Company provides for excess and obsolete inventories when conditions indicate that the inventory cost is not recoverable due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. Inventory provisions are measured as the difference between the cost of inventory and net realizable value to establish a lower cost basis for the inventories. As of SeptemberJune 30, 20222023 and December 31, 20212022, a provision for obsolescence of $3,194$2,897 and $2,213$3,258 was taken against inventory, respectively.

 

14

Property and Equipment, Net

 

Property and equipment, net consist of the following:

 

 

Useful Lives

 

September 30,

 

December 31,

  

Useful Lives

 

June 30,

 

December 31,

 
 

(in years)

  

2022

  

2021

  

(in years)

  

2023

  

2022

 

Lab equipment tooling and molds

 410  $8,056  $8,194  4 – 10  $3,576  $4,356 

Office furniture and equipment

 610  1,729  1,743  6 – 10  1,249  1,240 

Leasehold improvements

  

up to 10

  1,772  1,839   

up to 10

  621  794 

Computers and software

 3  2,037  1,939  3  934  906 

Vehicles

 57  37  37  5 – 7  37  37 

Clinical Training Units

  5   214   114 

Demo units

  5   214   214 

Total property and equipment

     13,845   13,866      6,631   7,547 

Less: Accumulated depreciation

     (11,665)  (11,197)     (4,991)  (5,690)

Total property and equipment, net

    $2,180  $2,669     $1,640  $1,857 

 

Depreciation expense amounted to $206$144 and $431$246 for the three months ended SeptemberJune 30, 20222023 and 20212022, respectively. Depreciation expense was $695$309 and $1,159$490 for the ninesix months ended SeptemberJune 30, 2023 30,2022and 2021,2022, respectively.

 

Other Current Assets

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Government remittances (1)

 $1,079 $1,322  $1,197 $1,602 

Consideration receivable from sale of subsidiaries

 853 1,405 

Consideration receivable from subsidiaries sale

 231 629 

Deferred financing costs

 419 223  4 301 

Sundry assets and miscellaneous

  1,000  808   552  1,170 

Total other current assets

 $3,351  $3,758  $1,984  $3,702 

 

(1)         Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.

 

Accrued Expenses and Other Current Liabilities

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Payroll and related expense

 $1,764 $1,770  $1,601 $2,244 

Accrued expenses

 6,390 6,584  4,023 5,045 

Commission accrual

 3,206 4,529  2,445 3,761 

Sales and consumption taxes

  5,975  6,629   4,994  5,617 

Total accrued expenses and other current liabilities

 $17,335  $19,512  $13,063  $16,667 

 

1511

 

Warranty Accrual

 

The following table provides the details of the change in the Company’s warranty accrual:

 

 

September 30,

 

December 31,

  

June 30,

 

December 31,

 
 

2022

  

2021

  

2023

  

2022

 

Balance as of the beginning of the period

 $1,753 $1,639  $1,482 $1,753 

Warranties issued during the period

 509 1,231  78 993 

Warranty costs incurred during the period

  (689)  (1,117)  (303)  (1,264)

Balance at the end of the period

 $1,573 $1,753  $1,257 $1,482 

Current

 1,147 1,245  880 1,074 

Long-term

  426  508   377  408 

Total

 $1,573 $1,753  $1,257 $1,482 

 

Finance Expenses

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2022

  

2021

  

2022

  

2021

 

Interest expense

 $1,153  $940  $2,979  $3,008 

Accretion on long-term debt and amortization of fees

  66   60   197   1,038 

Total finance expenses

 $1,219  $1,000  $3,176  $4,046 

The following table provides the details of the Company’s finance expenses:

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2023

  

2022

  

2023

  

2022

 

Interest expense

 $1,487  $969  $2,930  $1,827 

Accretion on long-term debt and amortization of fees

  66   65   131   130 

Total finance expenses

 $1,553  $1,034  $3,061  $1,957 

 

 

7.LEASES

The following presents the various components of lease costs. 

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2023

  

2022

  

2023

  

2022

 

Operating lease cost

 $503  $607  $1,013  $941 

Short-term lease cost

            

Total lease cost

 $503  $607  $1,013  $941 

The following table presents supplemental information relating to the cash flows arising from lease transactions. Cash payments related to short-term leases are not included in the measurement of operating lease liabilities, and as such, are excluded from the amounts below.

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
  

2023

  

2022

  

2023

  

2022

 

Operating cash outflows from operating leases

 $503  $607  $1,013  $941 

The following table presents the weighted-average lease term and discount rate for operating leases. 

  

At June 30,

 
  

2023

  

2022

 

Operating leases

        

Weighted-average remaining lease term (in years)

  3.44   4.29 

Weighted-average discount rate

  4.00%  4.00%

The following table presents a maturity analysis of expected undiscounted cash flows for operating leases on an annual basis for the next five years and thereafter.

Years ending December 31,

 

Operating leases

 

2023

 $780 

2024

  1,407 

2025

  1,228 

2026

  1,039 

2027

  594 

Thereafter

  544 

Imputed Interest (1)

  (355)

Total

 $5,237 

(1) Imputed interest represents the difference between undiscounted cash flows and cash flows.

12

8. INTANGIBLE ASSETS

 

Intangible assets net of accumulated amortization and goodwill were as follows:

 

 

At September 30, 2022

  

At June 30, 2023

 
 

Gross Amount

  

Accumulated Amortization

  

Net Amount

  

Gross Amount

  

Accumulated Amortization

  

Net Amount

 

Customer relationships

 $1,400 $(405) $995  $1,400 $(475) $925 

Brand

 2,500 (1,000) 1,500  2,500 (1,197) 1,303 

Technology

 16,900 (8,209) 8,691  16,900 (10,317) 6,583 

Supplier agreement

  3,000  (1,391)  1,609   3,000  (1,614)  1,386 

Total intangible assets

 $23,800  $(11,005) $12,795  $23,800  $(13,603) $10,197 

 

  

At December 31, 2021

 
  

Gross Amount

  

Accumulated Amortization

  

Net Amount

 

Customer relationships

 $1,400  $(336) $1,064 

Brand

  2,500   (803)  1,697 

Technology

  16,900   (6,103)  10,797 

Supplier agreement

  3,000   (1,165)  1,835 

Total intangible assets

 $23,800  $(8,407) $15,393 

  

At December 31, 2022

 
  

Gross Amount

  

Accumulated Amortization

  

Net Amount

 

Customer relationships

 $1,400  $(429) $971 

Brand

  2,500   (1,066)  1,434 

Technology

  16,900   (8,919)  7,981 

Supplier agreement

  3,000   (1,467)  1,533 

Total intangible assets

 $23,800  $(11,881) $11,919 

 

For the three months ended SeptemberJune 30, 20222023 and 20212022, amortization expense was $875$866 and $874,865, respectively. For the ninesix months ended SeptemberJune 30, 20222023 and 20212022,, amortization expense was $2,598$1,722 and $2,597,$1,722, respectively.

 

16

Estimated amortization expense for the next five fiscal years and all years thereafter are as follows:

 

Years ending December 31,

    

2022

 $875 

2023

 3,473  $1,751 

2024

 3,473  3,473 

2025

 3,004  3,004 

2026

 657  656 

2027

 657 

Thereafter

  1,313   656 

Total

 $12,795  $10,197 

 

 

8.9. COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company has various operating lease agreements, which expire on various dates.

The Company recognizes rent expense on a straight-line basis over the non-cancellable lease period and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. When leases contain escalation clauses, rent abatements and/or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease period.

Aggregate future minimum lease payments, and service and purchase commitments with manufacturers as of September 30, 2022 are as follows:

Years ending December 31,

 

Office Lease

  

Purchase and Service Commitments

  

Total

 

2022

 $863  $17,785  $18,648 

2023

  1,840   -   1,840 

2024

  1,372   -   1,372 

2025

  1,135   -   1,135 

2026

  1,017   -   1,017 

Thereafter

  1,170   -   1,170 

Total

 $7,397  $17,785  $25,182 

The total rent expense for all operating leases for the three months ended September 30,2022 and 2021 was $637 and $528, respectively. The total rent expense for all operating leases for the nine months ended September 30,2022 and 2021 was $1,950 and $1,623, respectively. 

 

Commitments

 

As of SeptemberJune 30, 20222023, the Company has non-cancellable purchase orders placed with its contract manufacturers in the amount of $16,506.$15.1 million. In addition, as of SeptemberJune 30, 20222023, the Company had $5,119$0.7 million of open purchase orders that can be cancelled with 270 days’ notice, except for a portion equal to 25% of the total amount representing the purchase of “long lead items”.items.”

 

OnAggregate future service and purchase commitments with manufacturers as of March 25, 2021, June 30, 2023the Company entered into an endorsement agreement for the services of Venus Williams, four-time Olympic Gold Medalist, seven-time Grand Slam Champion and entrepreneur, pursuant to which Ms. Williams will act are as a brand ambassador for Venus Bliss. The endorsement agreement expired on November 1, 2022.follows:

 

17

Years ending December 31,

 

Purchase and Service Commitments

 

2023

 $15,086 

2024 and Thereafter

   

Total

 $15,086 

Legal Proceedings

 

Purported Shareholder Class Actions

In 2018 and 2019,four putative shareholder class action complaints were filed against Restoration Robotics, Inc., certain of its former officers and directors, certain of its venture capital investors, and the underwriters of the initial public offering (“IPO”). Two claims, captioned Wong v. Restoration Robotics, Inc., et al., No.18CIV02609, and Li v. Restoration Robotics, Inc., et al., No.19CIV08173 (together, the “State Actions”), were filed in the Superior Court of the State of California, County of San Mateo, and assert claims under Sections 11,12(a)(2) and 15 of the 1933 Act. Two additional claims, captioned Guerrini v. Restoration Robotics, Inc., et al., No.5:18-cv-03712-EJD and Yzeiraj v. Restoration Robotics, Inc., et al., No.5:18-cv-03883-BLF (together, the “Federal Actions”), were filed in the United States District Court for the Northern District of California and assert claims under Sections 11 and 15 of the 1933 Act. The complaints in both the State Actions and Federal Actions alleged, among other things, that the Restoration Robotics’ Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with Restoration Robotics’ IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. The complaints sought unspecified monetary damages, other equitable relief and attorneys’ fees and costs. A settlement in the Federal Actions was granted final approval in the District Court on September 9, 2021. 

In the State Actions, the Plaintiffs filed a consolidated amended complaint on January 17, 2020 seeking unspecified monetary damages, other equitable relief and attorneys’ fees and costs. Following the Delaware Supreme Court reversal of the Chancery Court’s decision in Sciabacucchi v. Salzberg which held that exclusive federal forum provisions are valid under Delaware law, the Company filed a renewed motion to dismiss based on its federal forum selection clause on March 30, 2020, which was granted as to the Company and the individual defendants on September 1, 2020 and a judgement of dismissal was entered by the Court on September 22, 2020. On November 23, 2020, plaintiff filed a notice of appeal of the Court’s order granting the renewed motion to dismiss. The court of appeal heard oral argument related to the appeal on April 20, 2022, and on April 28, 2022, issued its opinion affirming the trial court’s dismissal of the State Actions based on the federal forum selection clause. On June 7, 2022, Plaintiff-Appellant Wong petitioned the California Supreme Court to review the appellate court’s opinion. The Company filed its Response to Plaintiff-Appellant Wong’s petition on June 27, 2022, and Plaintiff-Appellant Wong filed a Reply in Support of the Petition For Review on July 7, 2022. On July 27, 2022, the California Supreme Court denied Plaintiff-Appellant Wong’s petition for review. Plaintiff-Appellant Wong’s deadline to seek review in the United States Supreme Court was October 25, 2022, but no petition for review has been filed. 

 

On July 11, 2019, a verified shareholder derivative complaint was filed in the United States District Court for the Northern District of California, captioned Mason v. Rhodes, No. 5:19-cv-03997-NC. The complaint alleges that certain of Restoration Robotics’ former officers and directors breached their fiduciary duties, have been unjustly enriched and violated Section 14(a) of the 1934Exchange Act in connection with the IPO and Restoration Robotics’ 2018 proxy statement. The complaint seeks unspecified damages, declaratory relief, other equitable relief and attorneys’ fees and costs. On August 21, 2019, the District Court granted the parties’ joint stipulation to stay the Mason action. On June 21, 2021, the District Court granted the parties’ further stipulation to stay the Mason action andaction. On March 2, 2023, Plaintiff filed a stipulation voluntarily dismissing the case remains stayed. 

action. The District Court has not yet entered the stipulation.

 

1813

 
 

9.10. MAIN STREET TERM LOAN

 

On December 8, 2020, the Company executed a loan and security agreement (the "MSLP Loan Agreement"), a promissory note (the "MSLP Note"), and related documents for a loan in the aggregate amount of $50,000 for which City National Bank of Florida (“CNB”) will serve as a lender pursuant to the Main Street Priority Loan Facility as established by the Board of Governors of the Federal Reserve System Section 13(3) of the Federal Reserve Act (the “MSLP Loan”). On December 9, 2020, the MSLP Loan had been funded and the transaction was closed. The MSLP Note has a term of five years and bears interest at a rate per annum equal to 30-day LIBOR plus 3%. On December 8, 2023 8,2023and December 8, 2024, 8,2024,the Company must make an annual payment of principal plus accrued but unpaid interest in an amount equal to fifteen percent (15%) of the outstanding principal balance of the MSLP Note (inclusive of accrued but unpaid interest). The entire outstanding principal balance of the MSLP Note together with all accrued and unpaid interest is due and payable in full on December 8, 2025. 8,2025.The Company may prepay the MSLP Loan at any time without incurring any prepayment penalties. The MSLP Note provides for customary events of default, including, among others, those relating to a failure to make payment, bankruptcy, breaches of representations and covenants, and the occurrence of certain events. In addition, the MSLP Loan Agreement and MSLP Note contain various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of the Company’s assets, incur, create, or permit to exist additional indebtedness, or liens, to make dividends and other restricted payments, and to make certain changes to its ownership structure.

 

As of SeptemberJune 30, 20222023 and December 31, 20212022, the Company was in compliance with all required covenants.

 

The scheduled payments on the outstanding borrowings as of SeptemberJune 30, 20222023 are as follows:

 

Years ending December 31,

    

2022

 $781 

2023

  10,948 

2024

  9,314 

2025

  39,580 

Total

 $60,623 

   As of June 30, 2023 

2023

 $9,889 

2024

  10,239 

2025

  40,365 

Total

 $60,493 

 

1914

 
 

10.11. MADRYN LONG-TERM DEBT AND CONVERTIBLE NOTES

 

On October 11, 2016, Venus Concept Ltd., a wholly owned subsidiary of the Company ("Venus Ltd."), entered into a credit agreement as a guarantor with Madryn Health Partners, LP, as administrative agent, and certain of its affiliates as lenders (collectively, “Madryn”), as amended (the “Madryn Credit Agreement”), pursuant to which Madryn agreed to make certain loans to certain of Venus Ltd.’s subsidiaries (the “Subsidiary Obligors”). The Madryn Credit Agreement was comprised of four tranches of debt aggregating $70,000. As of September 30, 2020, the Subsidiary Obligors had borrowed $60,000 under the term A-1 and A-2 and B tranches of the Madryn Credit Agreement. Borrowings under the Madryn Credit Agreement were secured by substantially all of the Company’s assets and the assets of the Subsidiary Obligors. On the 24th payment date, which was September 30, 2022, the aggregate outstanding principal amount of the loans, together with any accrued and unpaid interest thereon and all other amounts due and owing under the loan agreement were to become due and payable in full. The Madryn Credit Agreement was terminated effective December 9, 2020 upon the funding and closing of the MSLP Loan as discussed below. Concept’s subsidiaries.

 

On December 9, 2020, contemporaneously with the MSLP Loan Agreement (Note 910), the Company and its subsidiaries, Venus Concept USA, Inc., a Delaware corporation (“ ("Venus USA”USA"), Venus Ltd., Venus Concept Canada Corp. ("Venus Ltd.Canada"), and the Madryn Noteholders (as defined below), entered into a Securities Exchange Agreement (the “Exchange Agreement”"Exchange Agreement") dated as of December 8, 2020, pursuant to which the Company (i) repaid $42,500on December 9, 2020, $42.5 million aggregate principal amount owed under the Madryn Credit Agreement, and (ii) issued, on December 9, 2020, to the Madryn Health Partners (Cayman Master), LP and Madryn Health Partners, LP (together the “Madryn Noteholders”(the "Madryn Noteholders") secured subordinated convertible notes in the aggregate principal amount of $26,695$26.7 million (the “Notes”"Notes"). The Madryn Credit Agreement was terminated effective December 9, 2020 upon the funding and closing of the MSLP Loan and the issuance of the Notes.

 

20

June 30, 2023, the Company had approximately $27.2 million principal and interest of convertible notes outstanding that were issued pursuant to the Exchange Agreement (as defined below).

The Notes will accrue interest at a rate of 8.0% per annum from the date of original issuance of the Notes to the third anniversary date of the original issuance and thereafter interest will accrue at a rate of 6.0% per annum. Under certain circumstances, in the case of an event of default under the Notes, the then-applicable interest rate will increase by 4.0% per annum. Interest is payable quarterly in arrears on the last business day of each calendar quarter of each year after the original issuance date, beginning on December 31, 2020. The Notes will mature on December 9, 2025, unless earlier redeemed or converted. In connection with the Exchange Agreement, the Company also entered into, by and among the Company, Venus USA, Venus Canada, Venus Ltd., and the Madryn Noteholders, (i) a Guaranty and Security Agreement dated as of December 9, 2020 (the "Madryn Security Agreement"), pursuant to which the Company agreed to grant Madryn a security interest in substantially all of its assets to secure the obligations under the Notes and (ii) a Subordination of Debt Agreement dated as of December 9, 2020 (the "CNB Subordination Agreement"). The security interests and liens granted to the Madryn Noteholders under the Madryn Security Agreement will terminate upon the earlier of (i) an assignment of the Notes (other than to an affiliate of the Madryn Noteholders) pursuant to the terms of the Exchange Agreement and (ii) the first date on which the outstanding principal amount of the Notes is less than $10,000. Obligations under the Notes are secured by substantially all of the assets of Venus Concept Inc. and its subsidiaries party to the Madryn Security Agreement. The Company’s obligations under the Notes and the security interests and liens created by the Madryn Security Agreement are subordinated to the Company’s indebtedness owing to CNB (including, but not limited, pursuant to the MSLP Loan Agreement (Note 910) and the CNB Loan Agreement, (Note 1112)) and any security interests and liens which secure such indebtedness owing to CNB. The Notes are convertible at any time into shares of the Company’s common stock, par value $0.0001 per share, calculated by dividing the outstanding principal amount of the Notes (and any accrued and unpaid interest under the Notes) by the initial conversion price of $3.25$48.75 per share. In connection with the Notes, the Company recognized interest expense of $546$540 and $540 during the three months ended SeptemberJune 30, 20222023 and 20212022,, respectively. TheIn connection with the Notes, the Company recognized interest expense of $1,086$1,074 and $1,613$1,074 during the ninesix months ended SeptemberJune 30, 20222023 and 20212022, respectively. The conversion feature, providing the Madryn Noteholders with a right to receive the Company’s shares upon conversion of the Notes, was qualified for a scope exception in ASC 815-10-15 and did not require bifurcation. The Notes also contained embedded redemption features that provided multiple redemption alternatives. Certain redemption features provided the Madryn Noteholders with a right to receive cash and a variable number of shares upon change of control and an event of default (as defined in the Notes). The Company evaluated redemption upon change of control and an event of default under ASC 815, Derivatives and Hedging, and determined that these two redemption features required bifurcation. These embedded derivatives were accounted for as liabilities at their estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the unaudited condensed consolidated statements of operations. The Company determined the likelihood of an event of default and change of control as remote as of SeptemberJune 30, 20222023, and December 31, 20212022, therefore a nominal value was allocated to the underlying embedded derivative liabilities as of SeptemberJune 30, 20222023, and December 31, 20212022.

 

The scheduled payments on the outstanding borrowings as of SeptemberJune 30, 20222023 are as follows:

 

Years ending December 31,

  

2022

 $546 
  As of June 30, 2023 

2023

 2,131  $1,608 

2024

 1,628  1,628 

2025

  28,217   28,217 

Total

 $32,522  $31,453 

 

For the three and ninesix months ended SeptemberJune 30, 20222023, the Company did not make any principal repayments. Pursuant to consent agreements entered into by and between the Company and certain of its subsidiaries as guarantors, Madryn and CNB as of June 30, 2023 and July 28, 2023, the Company paid the Q22023 interest payable under the Notes on June 30, 2023 by adding such Q22023 interest to the outstanding principal of the applicable Notes. Cash payment of the Q22023 interest under the Notes and all accrued and unpaid interest, was deferred until August 15, 2023 or such later date as the Madryn Noteholders may confirm from time to time in writing in their sole discretion.

 

2115

 
 

11.12. CREDIT FACILITY

 

On August 29, 2018, Venus Ltd. entered into an Amended and Restated Loan Agreement as a guarantor with CNB, as amended on March 20, 2020, December 9, 2020 and August 26, 2021 (the “CNB Loan Agreement”), pursuant to which CNB agreed to make certain loans and other financial accommodations to certain of Venus Ltd.’s subsidiaries to be used to finance working capital requirements. In connection with the CNB Loan Agreement, Venus Ltd. also entered into a guaranty agreement with CNB dated as of August 29, 2018, as amended on March 20, 2020, December 9, 2020 and August 26, 2021 (the “CNB Guaranty”), pursuant to which Venus Ltd. agreed to guaranty the obligations of its subsidiaries under the CNB Loan Agreement. On March 20, 2020, the Company also entered into a Security Agreement with CNB (the “CNB Security Agreement”), as amended on December 9, 2020 and August 26, 2021, pursuant to which it agreed to grant CNB a security interest in substantially all of our assets to secure the obligations under the CNB Loan Agreement. 

 

The CNB Loan Agreement contains various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of the Company’s assets, incur, create, or permit to exist additional indebtedness, or liens, to make dividends and certain other restricted payments, and to make certain changes to its management and/or ownership structure. The Company is required to maintain $3,000 in cash in a deposit account maintained with CNB at all times during the term of the CNB Loan Agreement. In addition, the CNB Loan Agreement contains certain covenants that require the Company to achieve certain minimum account balances, or a minimum debt service coverage ratio and a maximum total liability to tangible net worth ratio. If the Company fails to comply with these covenants, it will result in a default and require the Company to repay all outstanding principal amounts and any accrued interest. In connection with the CNB Loan Agreement, a loan fee of $1,000 was paid in equal installments on January 25, February 25, and March 25, 2021.

 

On August 26, 2021, the Company, Venus USA and Venus Canada entered into a Fourth Amended and Restated Loan Agreement (the “Amended CNB Loan Agreement”) with CNB, pursuant to which, among other things, (i) the maximum principal amount the revolving credit facility was reduced from $10,000 to $5,000 at the LIBOR 30-Day rate plus 3.25%, subject to a minimum LIBOR rate floor of 0.50%, and (ii) beginning December 10, 2021, the cash deposit requirement was reduced from $3,000 to $1,500, to be maintained with CNB at all times during the term of the Amended CNB Loan Agreement. The Amended CNB Loan Agreement is secured by substantially all of the Company’s assets and the assets of certain of its subsidiaries. On February 22, 2023, CNB notified the Company that it would be temporarily restricting advances under the Fourth Amended and Restated CNB Loan Agreement pursuant to its rights under Section 2 of the agreement. CNB and the Company continue to discuss lifting the restrictions on advances under the credit facility. However, CNB and the Company have not yet agreed to the criteria the Company must satisfy in order to lift the restrictions on advances under the credit facility.

 

As of SeptemberJune 30, 20222023, and December 31, 20212022, the Company was in compliance with all required covenants. An event of default under this agreement would cause a default under the MSLP Loan (see Note 910).

 

In connection with the Amended CNB Loan Agreement, the Company, Venus USA and Venus Canada issued a promissory note dated August 26, 2021, in favor of CNB (the “CNB Note”) in the amount of $5,000 with a maturity date of July 24, 2023 and the obligations of the Company pursuant to certain of the Company’s outstanding promissory notes were reaffirmed as subordinated to the indebtedness of the Company owing to CNB pursuant to a Supplement to Subordination of Debt Agreements dated as of August 26, 2021 (the “Subordination Supplement”) by and among Madryn Health Partners, LP, Madryn Health Partners (Cayman Master), LP, the Company and CNB.

 

22
16

12. GOVERNMENT ASSISTANCE PROGRAMS

 

Venus Concept Inc. and Venus USA, received funding in the total amount of $4,048 in connection with two Small Business Loans under the federal Paycheck Protection Program provided in Section 7(a) of the Small Business Act of 1953, as amended by the Coronavirus Aid, Relief, and Economic Security Act, as amended from time to time (the “PPP”).

Venus Concept Inc. entered into a U.S. Small Business Administration Note dated as of April 21, 2020 in favor of CNB pursuant to which the Company borrowed $1,665 original principal amount, which was funded on April 29, 2020 (the “Venus Concept PPP Loan”). The Venus Concept PPP Loan bears interest at 1% per annum and matures in two years from the date of disbursement of funds under the loan.

Venus USA entered into a U.S. Small Business Administration Note dated as of April 15, 2020 in favor of CNB. Venus USA borrowed $2,383 original principal amount, which was funded on April 20, 2020 (the “Venus USA PPP Loan” and together with the Venus Concept PPP Loan, individually each a “PPP Loan” and collectively, the “PPP Loans”). The terms of the Venus USA PPP Loan were substantially similar to the terms of the Venus Concept PPP Loan.

The Venus Concept PPP Loan contained certain covenants which, among other things, restrict the Company’s use of the proceeds of the PPP Loan to the payment of payroll costs, interest on mortgage obligations, rent obligations and utility expenses, require compliance with all other loans or other agreements with any creditor of the Company, to the extent that a default under any loan or other agreement would materially affect the Company’s ability to repay its PPP Loan and limit the Company’s ability to make certain changes to its ownership structure.

In 2021, through CNB, the Company applied for and received partial forgiveness of the Venus USA PPP Loan in the amount of $1,689 and the Venus Concept PPP Loan in the amount of $1,086. The Company repaid $407 during the three months ended March 31, 2022, and the remaining portion of the PPP Loans in the amount of $136 was fully repaid in April 2022. As of September 30, 2022, the Company had $niloutstanding under the PPP Loans ($543 as of December 31, 2021). 

23

 

13. COMMON STOCK RESERVED FOR ISSUANCE

 

The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to affect the exercise of all options granted and available for grant under the incentive plans and warrants to purchase common stock and preferred shares which are convertible to common stock.

 

 

September 30, 2022

  

December 31, 2021

  

June 30, 2023

  

December 31, 2022

 

Outstanding common stock warrants

 15,928,867  15,928,867  1,061,930  1,061,930 

Outstanding stock options and RSUs

 7,483,514  5,977,179  1,019,837 875,524 

Preferred shares

 3,790,755  3,790,755  2,872,518 2,123,443 

Shares reserved for conversion of future preferred share issuance

 1,209,245 1,209,245 

Shares reserved for conversion of future non-voting preferred share issuance

  80,617 

Shares reserved for conversion of future voting preferred share issuance

 7,860,916 609,891 

Shares reserved for future option grants and RSUs

 1,624,130 589,064  64,292 24,999 

Shares reserved for Lincoln Park

 21,814,471 5,222,867  711,180 1,054,299 

Shares reserved for Madryn Noteholders

  8,213,880  8,213,880   558,666  547,714 

Total common stock reserved for issuance

  60,064,862   40,931,857   14,149,339   6,378,417 

 

 

14. STOCKHOLDERS' EQUITY

 

Common Stock

 

The Company’s common stock confers upon its holders the following rights:

 

 

The right to participate and vote in the Company’s stockholder meetings, whether annual or special. Each share will entitle its holder, when attending and participating in the voting in person or via proxy, to one vote;

 

 

The right to a share in the distribution of dividends, whether in cash or in the form of bonus shares, the distribution of assets or any other distribution pro rata to the par value of the shares held by them; and

 

 

The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the shares held by them.

 

24

the Company’s shareholders held on May 10, 2023, the Company’s shareholders granted the Company’s Board of Directors discretionary authority to implement the Reverse Stock Split and to fix the specific consolidation ratio within a range of one-for-five (1-for-5) to one-for-fifteen (1-for-15). On May 11, 2023, the Company filed an amendment to the Company’s Certificate of Incorporation to implement the Reverse Stock Split based on a one-for-fifteen (1-for-15) consolidation ratio. The Company’s common shares began trading on the Nasdaq Capital Market on a reverse split-adjusted basis under the Company’s existing trade symbol “VERO” at the opening of the market on May 12, 2023. In accordance with U.S. GAAP, the change has been applied retroactively.

Equity Purchase Agreement with Lincoln Park

On June 16, 2020, the Company entered into the Equity Purchase Agreement with Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may sell to Lincoln Park up to $31,000 worth of shares of its common stock, par value $0.0001 per share, pursuant to its shelf registration statement. The purchase price of shares of common stock related to a future sale will be based on the then prevailing market prices of such shares at the time of sales as described in the Equity Purchase Agreement. The aggregate number of shares that the Company can sell to Lincoln Park under the Equity Purchase Agreement may in no case exceed 7,763,411517,560 shares (subject to adjustment) of common stock (which is equal to approximately 19.99% of the shares of the common stock outstanding immediately prior to the execution of the Equity Purchase Agreement) (the “Exchange Cap”), unless (i) stockholder approval is obtained to issue shares above the Exchange Cap, in which case the Exchange Cap will no longer apply, or (ii) with Equity Purchase Agreement equals or exceeds $3.9755$59.6325 per share (subject to adjustment) (which represents the minimum price, as defined under Nasdaq Listing Rule 5635(d), on the Nasdaq Global Market immediately preceding the signing of the Equity Purchase Agreement, such that the transactions contemplated by the Equity Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules. Also, at no time may Lincoln Park (together with its affiliates) beneficially own more than 9.99% of the Company’s issued and outstanding common stock. Concurrently with entering into the Equity Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration rights related to the shares of common stock issued under the Equity Purchase Agreement (the “Registration Rights Agreement”).

From commencement to expiry on July 1, 2022, the Company issued and sold to Lincoln Park 3,437,521229,139 shares of its common stock at an average price of $2.70$40.50 per share, and 209,56613,971 of these shares were issued to Lincoln Park as a commitment fee in connection with entering into the Equity Purchase Agreement (the “Commitment Shares”). The total value of the Commitment Shares of $620 together with the issuance costs of $123 were recorded as deferred issuance costs in the consolidated balance sheet at inception and were amortized into consolidated statements of stockholders’ equity proportionally based on proceeds received during the term of the Equity Purchase Agreement. In 2022, the Company issued 400,00026,666 shares of its common stock and the proceeds from common stock issuances as of SeptemberDecember 30,31, 2022 were $272, with no issuance costs. The proceeds in the amount of $272 were recorded in the condensed consolidated statements of cash flows as net cash proceeds from issuance of common stock. The Equity Purchase Agreement expired on July 1, 2022, and was replaced with the 2022 LPC Purchase Agreement discussed below.

 

2022 LPC Purchase Agreement with Lincoln Park

On July 12, 2022, the Company entered into a new equity agreement with Lincoln Park (thethe "2022 LPC Purchase Agreement"),Agreement with Lincoln Park, as the Equity Purchase Agreement expired on July 1, 2022. The 2022 LPC Purchase Agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may sell to Lincoln Park up to $11,000 of shares (the “Purchase Shares”) of its common stock, par value $0.0001 per share. Concurrently with entering into the 2022 LPC Purchase Agreement, the Company also entered into a registration rights agreement (the “2022 LPC Registration Rights Agreement”) with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration rights related to the shares issued under the 2022 LPC Purchase Agreement. The aggregate number of shares that the Company can issue to Lincoln Park under the 2022 LPC Purchase Agreement may not exceed 12,873,368858,224 shares of common stock, which is equal to 19.99% of the shares of common stock outstanding immediately prior to the execution of the 2022 LPC Purchase Agreement (the “2022 Exchange Cap”), unless (i) stockholder approval is obtained to issue shares of common stock in excess of the 2022 Exchange Cap, in which case the 2022 Exchange Cap will no longer apply, or (ii) the average price of all applicable sales of common stock to Lincoln Park under the 2022 LPC Purchase Agreement equals or exceeds the lower of (i) the Nasdaq official closing price immediately preceding the execution of the 2022 LPC Purchase Agreement or (ii) the arithmetic average of the five Nasdaq official closing prices for the common stock immediately preceding the execution of the 2022 LPC Purchase Agreement, plus an incremental amount to take into account the issuance of the commitment shares to Lincoln Park under the 2022 LPC Purchase Agreement, such that the transactions contemplated by the 2022 LPC Purchase Agreement are exempt from the 2022 Exchange Cap limitation under applicable Nasdaq rules. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the 2022 LPC Purchase Agreement if it would result in Lincoln Park beneficially owning more than 9.99% of the outstanding shares of common stock. Upon execution of the 2022 LPC Purchase Agreement, the Company issued 685,52945,701 shares of common stock to Lincoln Park as a commitment fee in connection with entering into the 2022 LPC Purchase Agreement at the total amount of $330. Through September 30,December 31, 2022, the Company issued an additional 500,000433,336 shares of common stock to Lincoln Park at an average price of $0.50$4.54 per share for a total value of $251.$1,970. During the six months ended June 30, 2023, the Company issued an additional 343,116 shares of common stock to Lincoln Park at an average price of $3.23 per share, for a total value of $1,109. Further information regarding the 2022 LPC Purchase Agreement is contained in the Company’s Form 8-K filed with the SEC on July 12, 2022.

The 2021 Private Placement

 

InOn December 15, 2021, the Companywe entered into a securities purchase agreement withpursuant to which we issued and sold to certain investors (collectively the “Investors”"2021 Investors") pursuant to which the Company issued and sold to the Investors an aggregate of 9,808,418653,894 shares of our common stock and 252,717 shares of our non-voting convertible preferred stock (the “Non-Voting Preferred Stock”), par value $0.0001 per share, and 3,790,755 shares of the convertible preferred stock, par value $0.0001 per share (the “Preferred Stock”), which are convertible into 3,790,755 shares of common stock upon receipt of stockholder approval (thea valid conversion notice by the Company from a 2021 Investor ("2021 Private Placement”Placement"). The 2021 Private Placement was completed on December 15, 2021. The gross proceeds from the securities sold in the 2021 Private Placement was $16,999.$17.0 million. The costs incurred with respect to the 2021 Private Placement totaled $259$0.3 million and were recorded as a reduction of the 2021 Private Placement proceeds in the consolidated statements of stockholders’ equity as presented inequity. These Non-Voting Preferred Stock shares were subsequently converted to common stock upon issuance of the 20212022 Annual Report on Form 10-K filed with the SEC on March 28, 2022.Private Placement described below.

 

2517

 

Preferred Stock issued in December 2021

 

As noted above, in December 2021, the Company issued and sold to the 2021Investors an aggregate of 3,790,755252,717 shares of the Non-Voting Preferred Stock. The terms of the Non-Voting Preferred Stock were governed by a Certificate of Designation filed by the Company with the Secretary of State of the State of Delaware on December 14, 2021. On May 15, 2023, the Company filed with the Delaware Secretary of State a Certificate of Elimination with respect to the Company’s Non-Voting Preferred Stock, thereby returning the unused share balance to the status of authorized but unissued shares of “blank check” preferred stock of the Company. Refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC for a summary of the material terms and information regarding the issuance of the Non-Voting Preferred Stock.

The 2022 Private Placement


In
November 2022, we entered into a securities purchase agreement with certain investors (collectively, the “2022 Investors”) pursuant to which the Company issued and sold to the 2022 Investors an aggregate of 116,668 shares of common stock, par value $0.0001 per share, and 3,185,000 shares of voting convertible preferred stock, par value $0.0001 per share (the "Voting Preferred Stock"), which are convertible into 2,123,443 shares of common stock upon receipt of a valid conversion notice from a 2022 Investor or at the option of the Company within 30 days following the occurrence of certain events (the "2022 Private Placement"). The 2022 Private Placement was completed on November 18, 2022. The gross proceeds from the securities sold in the 2022 Private Placement was $6,720. The costs incurred with respect to the 2022 Private Placement totaled $202 and were recorded as a reduction of the 2022 Private Placement proceeds in the consolidated statements of stockholders’ equity. Further information regarding the 2022 Private Placement is contained in the Company’s Form 8-K filed with the SEC on November 18, 2022.

Voting Preferred Stock issued in November 2022

As noted above, in November 2022, the Company issued and sold to certain 2022 Investors an aggregate of 3,185,000 shares of Voting Preferred Stock. The terms of the Voting Preferred Stock are governed by a Certificate of Designation filed by the Company with the Secretary of State of the State of Delaware on December 14, 2021.November 17, 2022. The following is a summary of the material terms of the Voting Preferred Stock:

 

 

Voting Rights. The Voting Preferred Stock has no voting rights except as required by law and except thatvotes with the consent of the holders of a majority of outstanding shares of the PreferredCommon Stock will be required to amend the terms of the Preferred Stock or take certain other actions with respect to the Preferred Stock.on an as-converted basis.

 

 

Liquidation. TheEach share of Voting Preferred Stock does not havecarries a liquidation preference, upon any liquidation, dissolution or winding-upsenior to the Common Stock in an amount equal to the greater of (a) $30.00 (being the Company.issuance price) and (b) the amount that would be distributed in respect of such share of Voting Preferred Stock if it were converted into Common Stock and participated in such liquidating distribution with the other shares of Common Stock.

 

 

Conversion. The Voting Preferred Stock is automatically convertiblewill convert into shares of common stock, basedCommon Stock on an initiala one for 0.6667 basis (i) at the option of a 2022 Investor upon delivery of a valid conversion ratio of 1:1, as adjusted in accordance withnotice to the Certificate of Designation, upon receiptCompany or (ii) at the option of the approvalCompany within 30 days following the earlier to occur of (a) the date on which the volume-weighted average price of the Company’s stockholders. The Company isCommon Stock has been greater than or equal to $18.75 for not30 permitted to issue any shares of common stock upon conversion of the Preferred Stock to the extent that the issuance of such shares of common stock would exceed 9.99% of the Company’s outstanding shares of common stock as ofconsecutive trading days and (b) the date on which the Company has reported two consecutive fiscal quarters of the initial issuance of the Preferred Stock (the “Ownership Limitation”). The Ownership Limitation will be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction.positive cash flow. 

 

 

Dividends. NoEach share of Voting Preferred Stock is entitled to participate in dividends will be paid onand other non-liquidating distributions (if, as and when declared by the outstanding sharesBoard of the PreferredCompany) on an as-converted basis, pari passu with the Common Stock.

 

 

Redemption. The Voting Preferred Stock is not redeemable at the election of the Company or at the election of the holder.

 

 

Maturity. The Voting Preferred Stock shall be perpetual unless converted.

 

Upon issuance,The 2023 Multi-Tranche Private Placement

In May 2023, we entered into a securities purchase agreement (the "2023 Multi-Tranche Private Placement Stock Purchase Agreement") with certain investors (collectively, the effective conversion price"2023 Investors") pursuant to which the Company may issue and sell to the 2023 Investors up to $9,000,000 in shares (the "2023 Multi-Tranche Private Placement") of the Preferred Stock of $1.25newly-created senior convertible preferred stock, par value $0.0001 per share was lower than(the “Senior Preferred Stock”), in multiple tranches from time to time until December 31, 2025, subject to a minimum aggregate purchase amount of $500,000 in each tranche. The initial sale in the market price of the Company’s common stock2023 Multi-Tranche Private Placement occurred on the date of issuance of the Preferred Stock of $1.29 per share; as a result,May 15, 2023, under which the Company recordedsold the beneficial conversion feature2023 Investors 280,899 shares of $152 in accumulated paid in capital (“APIC”). Because the Preferred Stock is perpetual, it is carried at the amount recorded at inception. Upon conversion of the Preferred Stock, the beneficial conversion feature will be accounted for as a deemed dividend.

The Company evaluated theSenior Preferred Stock for liability or equity classification in accordance withan aggregate purchase price of $2,000,000 (the "Initial Placement"). The Company expects to use the provisions of ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the Preferred Stock did not meet the definitionproceeds of the liability instruments defined thereunderInitial Placement, after the payment of transaction expenses, for convertible instruments. Specifically, the Preferred Stockgeneral working capital purposes. The following is not mandatorily redeemable and does not embody an obligation to buy back the shares outsidea summary of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Preferred Stock would be recorded as permanent equity, not temporary equity, based on the guidance of ASC 480 given that the holders of equally and more subordinated equity would be entitled to also receive the same form of consideration upon the occurrencematerial terms of the event that gives rise to the redemption or events of redemption that are within the control of the Company.Senior Preferred Stock:

 

Voting Rights. The Senior Preferred Stock has aggregate number of votes equal to the product of (a) the quotient of (i) the aggregate purchase price paid under the Stock Purchase Agreement for all shares of Senior Preferred Stock issued and outstanding as of such time, divided by (ii) the highest purchase price paid by a holder for a share of Senior Preferred Stock prior to or as of such time, multiplied by (b) two. Such formula ensures that no share of senior preferred stock will ever have more than two votes per share, with such number of votes subject to reduction (but not increase) depending on the pricing of future sales of Senior Preferred Stock in the Private Placement. The Senior Preferred Stock votes with the Company’s common stock on all matters submitted to holders of common stock and does not vote as a separate class.

Since the Preferred Stock was sold as a unit with the common stock, the proceeds received were allocated to each instrument on a relative fair value basis. Total net proceeds of $16,740 reduced by $152 of the beneficial conversion feature were allocated as follows: $4,514 to the Preferred Stock and $12,074 to shares of common stock. The Preferred Stock and common stock issued in the 2021 Private Placement were recorded at par value of $0.0001 with the excess of par value recorded in APIC.

Liquidation. Each share of Senior Preferred Stock carries a liquidation preference, senior to the Common Stock and Voting Preferred Stock, in an amount equal to the product of the Purchase Price for such share, multiplied by 2.50.

Conversion. The Senior Preferred Stock will convert into shares of Common Stock on a one for 2.6667 basis at the option of (a) the investors at any time or (b) the Company within 30 days following the date on which the 30-day volume-weighted average price of the common stock exceeds the product of (i) the Purchase Price for the shares of senior preferred stock to be converted, multiplied by (ii) 2.75.

Dividends. Each share of Senior Preferred Stock is entitled to participate in dividends and other non-liquidating distributions (if, as and when declared by the Board of the Company) on an as-converted basis, pari passu with the Common Stock and Voting Preferred Stock.

Redemption. The Senior Preferred Stock is not redeemable at the election of the Company or at the election of the holder.

Maturity. The Senior Preferred Stock shall be perpetual unless converted.

 

2618

 

2010 Share Option Plan

 

In November 2010, the Company’s Board of Directors (the “Board”) adopted a share option plan (the “2010 Share Option Plan”) pursuant to which shares of the Company’s common stock are reserved for issuance upon the exercise of options to be granted to directors, officers, employees and consultants of the Company. The 2010 Share Option Plan is administered by the Board, which designates the options and dates of grant. Options granted vest over a period determined by the Board, originally had a contractual life of seven years, which was extended to ten years in November 2017 and are non-assignable except by the laws of descent. The Board has the authority to prescribe, amend and rescind rules and regulations relating to the 2010 Share Option Plan, provided that any such amendment or rescindment that would adversely affect the rights of an optionee that has received or been granted an option shall not be made without the optionee’s written consent. As of SeptemberJune 30, 20222023, the number of shares of the Company’s common stock reserved for issuance and available for grant under the 2010 Share Option Plan was 400,812 (212,6502,738 (6,284 as of December 31, 20212022).

 

2019 Incentive Award Plan

 

The 2019 Incentive Award Plan (the “2019 Plan”) was originally established under the name Restoration Robotics, Inc., as the 2017 Incentive Award Plan. It was adopted by the Board on September 12, 2017 and approved by the Company’s stockholders on September 14, 2017. The 2017 Incentive Award Plan was amended, restated, and renamed as set forth above, and was approved by the Company’s stockholders on October 4, 2019.

 

Under the 2019 Plan, 450,00030,000 shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, performance stock awards, performance stock unit awards, restricted stock awards, restricted stock unit awards and other stock-based awards, plus the number of shares remaining available for future awards under the 2019 Plan as of the date we completed our business combination with Venus Ltd. and the business of Venus Ltd. became the primary business of the Company (the “Merger”). As of SeptemberJune 30, 20222023, there were 1,223,31861,554 shares of common stock available under the 2019 Plan (376,414(18,715 as of December 31, 20212022). The 2019 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year from 2020 and ending in 2029 equal to the lesser of (A) four percent (4.00%) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by the Board.

 

The Company recognized stock-based compensation for its employees and non-employees in the accompanying unaudited condensed consolidated statements of operations as follows:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Cost of sales

 $31  $8  $52  $23  $11  $13  $26  $21 

Sales and marketing

 139 211 448 652 

Selling and marketing

 76  134  185  309 

General and administrative

 317 289 868 850  251  322  551  551 

Research and development

  64  28  184  77   31   89   88   120 

Total stock-based compensation

 $551  $536  $1,552  $1,602  $369  $558  $850  $1,001 

 

2719

 

Stock Options

 

The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Expected term (in years)

 6.00  6.00  6.00  6.00  6.00  6.00  6.00  6.00 

Risk-free interest rate

 2.96% 0.98% 2.56-2.96% 0.98-1.09% 3.37% 2.92% 3.37-3.41% 2.56-2.92%

Expected volatility

 42.93% 43.66% 42.59% 44.69% 42.72% 42.89% 42.98% 42.56%

Expected dividend rate

 0% 0% 0% 0% 0% 0% 0% 0%

 

Expected Term—The expected term represents management’s best estimate for the options to be exercised by option holders.

 

Volatility—Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry that are considered to be comparable to the Company’s business over a period equivalent to the expected term of the stock-based awards.

 

Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the stock-based awards’ expected term.

 

Dividend Rate—The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future.

 

Fair Value of Common Stock— Prior to the Merger, Venus Ltd. used the price per share in its latest sale of securities as an estimate of the fair value of its ordinary shares. After the closing of the Merger, the fair value of the Company’s common stock is used to estimate the fair value of the stock-based awards at grant date.

 

The following table summarizes stock option activity under the Company’s stock option plans:

 

  

Number of Shares

  

Weighted- Average Exercise Price per Share, $

  

Weighted- Average Remaining Contractual Term

  

Aggregate Intrinsic Value

 

Outstanding – January 1, 2022

  5,977,179  $3.72   7.20  $136 

Options granted

  2,383,250   1.27         

Options exercised

  (16,464)  1.59         

Options forfeited/cancelled

  (1,249,201)  4.20       

Outstanding - September 30, 2022

  7,094,764  $2.82   7.55  $ 

Exercisable – September 30, 2022

  3,146,660  $3.99   5.75  $ 

Expected to vest – after September 30, 2022

  3,948,104  $1.89   8.99  $ 
  

Number of Shares

  

Weighted- Average Exercise Price per Share, $

  

Weighted- Average Remaining Contractual Term

  

Aggregate Intrinsic Value

 

Outstanding – January 1, 2023

  849,600  $25.05   8.23  $209 

Options granted

  211,031   2.89   -    

Options exercised

  -   -   -    

Options forfeited/cancelled

  (43,462)  35.07   -    

Outstanding – June 30, 2023

  1,017,169   20.05   7.92  $ 

Exercisable – June 30, 2023

  276,841   48.22   5.26  $ 

Expected to vest – after June 30, 2023

  740,328  $9.51   8.91  $ 

 

2820

 

The following tables summarize information about stock options outstanding and exercisable at SeptemberJune 30, 20222023:

 

  

Options Outstanding

  

Options Exercisable

 

Exercise Price Range

 

Number

  

Weighted average remaining contractual term (years)

  

Weighted average Exercise Price

  

Options exercisable

  

Weighted average remaining contractual term (years)

  

Weighted average Exercise Price

 

$0.67 - $3.64

  6,188,582   7.90  $2.13   2,295,735   5.99  $2.65 

$4.26 - $7.95

  860,692   5.22   6.62   806,450   5.10   6.64 

$12.45 - $26.10

  26,543   6.00   18.09   25,528   6.00   18.11 

$27.00 - $33.00

  10,768   2.47   27.32   10,768   2.47   27.32 

$36.00 - $94.65

  8,179   5.04   45.65   8,179   5.04   45.65 
   7,094,764   7.55  $2.82   3,146,660   5.75  $3.99 
  

Options Outstanding

  

Options Exercisable

 

Exercise Price Range

 

Number

  

Weighted average remaining contractual term (years)

  

Weighted average Exercise Price

  

Options exercisable

  

Weighted average remaining contractual term (years)

  

Weighted average Exercise Price

 

$2.82 - $54.60

  967,750   8.12  $15.19   228,587   5.55  $33.94 

$63.90 - $119.25

  46,638   3.92   99.45   45,473   3.85   99.76 

$186.75 - $382.50

  1,630   5.24   271.36   1,630   5.24   271.36 

$405.00 - $438.75

  644   1.79   405.21   644   1.79   405.21 

$540.00 - $958.50

  507   4.44   691.99   507   4.44   691.99 
   1,017,169   7.92  $20.05   276,841   5.26  $48.22 

 

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The total intrinsic value of options exercised were $nil and $19$nil for the three months ended SeptemberJune 30, 2023 30,2022and 2021,2022, respectively. The total intrinsic value of options exercised were $nil and $nil and $285 for the ninesix months ended SeptemberJune 30, 2023 30,2022and 2021,2022, respectively.

 

The weighted-average grant date fair value of options granted was $0.58$3.38 and $2.09$10.05 per share for the three months ended SeptemberJune 30, 2023 30,2022and 2021,2022, respectively. The weighted-average grant date fair value of options granted was $1.27$2.89 and $2.33$20.10 per share for the ninesix months ended SeptemberJune 30, 2023 30,2022and 2021,2022, respectively. The fair value of options vested during the three months ended SeptemberJune 30, 2023 30,and 2022 was $322 and 2021 was $317 and $380,$411, respectively. The fair value of options vested during the ninesix months ended SeptemberJune 30, 2023 30,and 2022 was $681 and 2021 was $1,197 and $1,180,$775, respectively.

 

Restricted Stock Units 

 

The following table summarizes information about RSUs outstanding at SeptemberJune 30, 20222023:

 

 

Number of Shares

 

Weighted- Average Grant Date Fair Value per Share, $

  

Number of Shares

  

Weighted- Average Grant Date Fair Value per Share, $

 

Outstanding – January 1, 2022

   $ 

Outstanding – January 1, 2023

 25,918  $19.50 

RSUs granted

 396,250 1.30     

RSUs forfeited/cancelled

  (7,500)  1.38  (1,250) 20.70 

Outstanding - September 30, 2022

  388,750  $1.30 

RSUs exercised

  (22,000)  20.70 

Outstanding - June 30, 2023

  2,668  $8.70 

 

2921

 
 

15. INCOME TAXES

 

The Company generated a loss and recognized $162$189 of tax expense for the three months ended June 30, 2023, and $18 of tax benefit for the three months ended SeptemberJune 30, 2022, and $616 of tax expense for the three months ended September 30, 2021, respectively. The Company generated a loss and recognized $92$424 of tax expense for the ninesix months ended SeptemberJune 30, 20222023, , and $609$254 of tax expense for the ninesix months ended SeptemberJune 30, 20212022, , respectively.  A reconciliation of income tax (benefit) expense is as follows:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Loss before income taxes

 $(14,658) $(8,222) $(33,552) $(17,422) $(7,132) $(10,530) $(16,520) $(18,894)

Theoretical tax (expense) benefit at the statutory rate (21.0% in 2022 and 2021)

 (3,078) (1,727) (7,046) (3,659)

Theoretical tax expense at the statutory rate (21% in 2023 and 2022)

 (1,484) (2,211) (3,456) (3,968)

Differences in jurisdictional tax rates

 (654) (313) (1,247) (716) (281) (341) (548) (593)

Valuation allowance

 3,142 2,388 7,327 4,687  1,890  2,118  4,332  4,185 

Non-deductible expenses

 427 268 1,058 207  65  418  97  631 

Other

  1      90   (1)  (2)  (1)  (1)

Total income tax (benefit) provision

  (162)  616   92   609 

Total income tax provision (recovery)

  189  (18)  424  254 

Net loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

 

Income tax expense or benefit is recognized based on the actual loss incurred during the three and ninesix months ended SeptemberJune 30, 20222023 and 20212022, respectively.

 

 

16. SEGMENT AND GEOGRAPHIC INFORMATION

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment, as the CODM reviews financial information presented on a consolidated basis accompanied by disaggregated information about revenues by geography and type for purposes of making operating decisions, allocating resources, and evaluating financial performance. The Company does not assess the performance of individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues by geography and type.

 

Revenue by geographic location, which is based on the product shipped to location, is summarized as follows:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

United States

 $11,774  $12,259  $38,319  $35,345  $9,757  $13,417  $20,498  $26,546 

International

  9,765   12,304   36,892   37,643   10,318   13,849   20,108   27,126 

Total revenue

 $21,539  $24,563  $75,211  $72,988  $20,075  $27,266  $40,606  $53,672 

 

As of SeptemberJune 30, 20222023, long-lived assets in the amount of $13,358$10,562 were located in the United States and $1,626$1,275 were located in foreign locations. As of December 31, 20212022, long-lived assets in the amount of $16,090$12,346 were located in the United States and $1,972$1,431 were located in foreign locations.

 

3022

 

Revenue by type is a key indicator for providing management with an understanding of the Company’s financial performance, which is organized into four different categories:

 

1.    Lease revenue – includes all system sales with typical lease terms of 36 months.

 

2.    System revenue – includes all systems sales with payment terms within 12 months.

 

3.    Product revenue – includes skincare, hair and other consumables payable upon receipt.

 

4.    Service revenue – includes NeoGraft technician services, ad agency services and extended warranty sales.

 

The following table presents revenue by type:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Lease revenue

 $7,193  $12,634  $29,490  $33,958  $4,311  $11,874  $10,072  $22,297 

System revenue

 10,416  8,022  33,838  26,526  12,313  11,548  23,377  23,422 

Product revenue

 3,125  2,961  9,702  9,330  2,586  3,080  5,532  6,577 

Service revenue

  805   946   2,181   3,174   865   764   1,625   1,376 

Total revenue

 $21,539  $24,563  $75,211  $72,988  $20,075  $27,266  $40,606  $53,672 

 

 

17. RELATED PARTY TRANSACTIONS

 

All amounts were recorded at the exchange amount, which is the amount established and agreed to by the related parties. The following are transactions between the Company and parties related through employment.

 

Distribution agreements

 

On January 1, 2018, the Company entered into a Distribution Agreement with Technicalbiomed Co., Ltd. (“TBC”), pursuant to which TBC will continue to distribute the Company’s products in Thailand. A former senior officer of the Company is a 30.0% shareholder of TBC. For the three months ended SeptemberJune 30, 20222023 and 20212022, TBC purchased products in the amount of $192$114 and $66,$329, respectively, under this distribution agreement. These sales are included in products and services revenue. For the ninesix months ended SeptemberJune 30, 20222023 and 20212022,, TBC purchased products in the amount of $928$322 and $194, respectively,$736, respectively, under this distribution agreement. These sales are included in products and services revenue.

 

In 2020, the Company made several strategic decisions to divest itself of underperforming direct sales offices and sold its share in several subsidiaries, including its 55.0% shareholding in Venus Concept Singapore Pte. Ltd. ("Venus Singapore"). On January 1, 2021, the Company entered into a distribution agreement with Aexel Biomed Pte Ltd. (“Aexel Biomed”), formerly Venus Singapore, pursuant to which Aexel Biomed will continue to distribute the Company’s products in Singapore. A former senior officer of the Company is a 45.0% shareholder of Aexel Biomed. During the three months ended SeptemberJune 30, 20222023 and 20212022, Aexel Biomed purchased products in the amount of $57$62 and $51,$141, respectively, under the distribution agreement. During the ninesix months ended SeptemberJune 30, 20222023 and 20212022,, Aexel Biomed purchased products in the amount of $376$122 and $165,$319, respectively, under the distributiondistributions agreement. These sales are included in products and services revenue.

 

3123

 
 

18. SUBSEQUENT EVENTS

 

SeparationOn July 6, 2023, the Company and the 2023 Investors entered into an amendment to the 2023 Multi-Tranche Private Placement Stock Purchase Agreement (the “Amendment”). The Amendment (a) clarifies the appropriate date pursuant to which the purchase price for each share of Domenic SerafinoSenior Preferred Stock to be sold in the Private Placement is determined (such that the purchase price shall be equal to the “Minimum Price” as Chief Executive Officerset forth in Nasdaq Listing Rule 5635(d)) and (b) permits the Company to specify a desired closing date (subject to approval by the 2023 Investors) for each sale in the 2023 Multi-Tranche Private Placement. 

 

On October 3, 2022,July 12, 2023, the Board announced the separation of Domenic Serafino as Chief Executive Officer (the “CEO”) and member of the Board, effective October 2, 2022. This separation was not the result of any specific disagreement about strategy with management or the Board, inappropriate action by CEO, violation of company policy or any accounting irregularity. In connection with Mr. Serafino’s departure, the Company and Mr. Serafino are discussing the terms of a separation agreement setting forth the terms of his separation from the Company. Refer to the 82023-K filed with Investors consummated the SEC on October 3, 2022 second tranche in the 2023 Multi-Tranche Private Placement, under which the Company sold the 2023 Investors 500,000 shares of Senior Preferred Stock for more information. an aggregate purchase price of $2,000,000 (the “Second Placement”). The Company expects to use the proceeds of the Second Placement, after the payment of transaction expenses, for general working capital purposes.

 

Appointment of Chief Executive Officer

On October 3, 2022, the Board announced the appointment of Rajiv De Silva as CEO, effective October 2, 2022. In connection with his appointment as CEO, Mr. De Silva entered into an employment agreement with the Company (the “Employment Agreement”) for a term to continue indefinitely until Mr. De Silva resigns or is terminated in accordance with the terms and conditions of the Employment Agreement. Pursuant to the terms of the Employment Agreement, Mr. De Silva is entitled to an annual base salary of $525 (“Base Salary”). Mr. De Silva will be eligible to earn an annual incentive bonus equal to seventy-five percent (75%) of his Base Salary and an equity award. Upon execution of the Employment Agreement, Mr. De Silva will be granted employee stock options to purchase 3,300,000 shares in the Company at an exercise price equal to the closing market price on the date of grant. Such shares shall vest as follows: 25% shall vest on the first anniversary of the date of grant and the remaining 75% of such shares shall vest quarterly at a rate of 6.25% per quarter, pursuant and subject to Mr. De Silva’s execution and return of the Company’s Stock Option Agreement. Refer to the 8-K filed with the SEC on October 3, 2022 for more information.

Appointment of President and Chief Business Officer

On October 11, 2022, the Company announced the appointment of Dr. Hemanth Varghese as President and Chief Business Officer, effective October 17, 2022.  In connection with his appointment as President and Chief Business Officer of the Company, Dr. Varghese entered into an employment agreement with Venus Concept Canada Corp. (the "Varghese Employment Agreement") for a term to continue indefinitely until Dr. Varghese resigns or is terminated in accordance with the terms and conditions of the Varghese Employment Agreement. Pursuant to the terms of the Varghese Employment Agreement, Dr. Varghese is entitled to an annual base salary of $370 ("Annual Base Salary"). Dr. Varghese will be eligible to earn an annual incentive bonus equal to 60% of his Annual Base Salary and an equity award. Upon the effective date of the Varghese Employment Agreement, Dr. Varghese will be granted employee stock options to purchase 1,100,000 shares in the Company at an exercise price equal to the closing market price on the date of grant. Such shares shall vest as follows: 25% shall vest on the first anniversary of the date of grant and the remaining 75% of such shares shall vest quarterly over 3 years thereafter, pursuant and subject to Dr. Varghese’s execution and return of the Company’s Stock Option Agreement.

Sale of Stock to LPC

Between October 3,2022, and November 8,2022, the Company issued 2,000,000 shares of common stock to Lincoln Park at an average price of $0.29 per share. See Note 14 for further information regarding the 2022 LPC Purchase Agreement. 

 

 

3224

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in in Part I, Item IA “Risk Factors” of our Annual Report on Form 10-K. Any statements contained in this Quarterly Report on Form 10-Q that are not historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends.

 

The factors which we currently believe could have a material adverse effect on our business operations and financial performance and condition include, but are not limited to, the following risks and uncertainties:

 

•    our dependency on the subscription-based model, which exposes us to the credit risk of our customers over the life of each subscription agreement;

•    our customers’ failure to make payments under their subscription agreements;

•    our need to obtain, maintain and enforce our intellectual property rights;

•    the extensive governmental regulation and oversight in the countries in which we operate and our ability to comply with the applicable requirements;

•    the possibility that our systems may cause or contribute to adverse medical events that could harm our reputation, business, financial condition and results of operations;

•    a significant portion of our operations are located in Israel and therefore our business, financial condition and results of operations may be adversely affected by political, economic and military conditions there;

•    our ability to come into, and remain in, compliance with the listing requirements of the Nasdaq Capital Market;

•    the volatility of our stock price;

•    our dependency on one major contract manufacturer in Israel exposes us to supply disruptions should that facility be subject to a strike, shutdown, fire flood or other natural disaster;

•    our reliance on the expertise and retention of management;

•    our ability to access the capital markets and/or obtain credit on favorable terms;

•    inflation, currency fluctuations and currency exchange rates;

•    global supply disruptions; and

•    global economic and political conditions and uncertainties, including but not limited to the Russia-Ukraine conflict.conflict; and 

 

The risks•    the expected timing, proceeds and impactsother details with respect to future sales of senior preferred stock, if any, in the COVID-19 pandemic appear to have largely subsided; however, new variants may continue to impact key macro-economic indicators such as unemployment, GDP and supply chain logistics and may have a material impact on our business, financial position, results of operations and liquidity. 2023 Multi-Tranche Private Placement.

You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on these statements. The forward-looking statements are based on information available to us as of the filing date of this Quarterly Report on Form 10-Q. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report on Form 10-Q. 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion contains managements discussion and analysis of our financial condition and results of operations and should be read together with the unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarter ended SeptemberJune 30, 20222023 (Form 10-Q), with our audited consolidated financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 20212022 (Form 10-K), our Form 10-Q for the quarter ended March 31, 2022 and June 30, 2022, respectively,  filed with the SECand other filings we have made with the SEC. 

 

Overview

 

We are an innovative global medical technology company that develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. Our systems have been designed on cost-effective, proprietary and flexible platforms that enable us to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. In the three and ninesix months ended SeptemberJune 30, 20222023 and 2021,2022, respectively, a substantial majority of our systems delivered in North America were in non-traditional markets. As we grow our ARTAS hair restoration business and expand robotics offerings through the AI.ME™ platform we expect our penetration into the core practices of dermatology and plastic surgery to increase.

 

3325

 

We have had recurring net operating losses and negative cash flows from operations. As of SeptemberJune 30, 20222023 and December 31, 2021,2022, we had an accumulated deficit of $214.2$241.7 million and $180.4$224.1 million, respectively. Until we generate revenue at a level to support our cost structure, we expect to continue to incur substantial operating losses and negative cash flows from operations. In order to continue our operations, we must achieve profitability and/or obtain additional equity investment or debt financing. Until we achieve profitability, we plan to fund our operations and capital expenditures with cash on hand, borrowings and issuances of capital stock. As of SeptemberJune 30, 20222023 and December 31, 20212022, we had cash and cash equivalents of $6.8$6.1 million and $30.9$11.6 million, respectively. 

 

While the impact of Covid-19 on our business has largely subsided, we continue to closely monitor all Covid-19 developments, including its impact on our customers, employees, suppliers, vendors, business partners, and distribution channels. In addition, theThe global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases to inflation rates, rising interest rates, foreign currency impacts and declines in consumer confidence, and declines in economic growth. All these factors point to uncertainty about economic stability, and the severity and duration of these conditions on our business cannot be predicted.

 

Venus Viva®,Venus Viva® MD, Venus Legacy®, Venus Concept®, Venus Versa®, Venus Fiore®, Venus Freedom™, Venus Bliss™, Venus Bliss Max™, NeoGraft®, Venus Glow™®, ARTAS®, ARTAS iX®, and AIME™, are trademarks of the Company and its subsidiaries. Our logo and our other trade names, trademarks and service marks appearing in this document are our property. Other trade names, trademarks and service marks appearing in this document are the property of their respective owners. Solely for convenience, our trademarks and trade names referred to in this document appear without the TM or the ® symbol, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names.

 

Equity Purchase Agreement with Lincoln Park

 

On June 16, 2020, we entered into the Equity Purchase Agreement with Lincoln Park, which provided that, upon the terms and subject to the conditions and limitations set forth therein, we may sell to Lincoln Park up to $31.0 million of shares of our common stock pursuant to our shelf registration statement. The purchase price of shares of common stock related to a future sale was based on the then prevailing market prices of such shares at the time of sales as described in the Equity Purchase Agreement. Concurrently with entering into the Equity Purchase Agreement, we also entered into the Registration Rights Agreement. During the nine months ended September 30, 2022, we sold to Lincoln Park 0.4 million shares of our common stock and raised net cash proceeds of $0.3 million under the Equity Purchase Agreement. See ‘‘—Liquidity and Capital Resources’’ below. The Equity Purchase Agreement expired on July 1, 2022 and was replaced by the 2022 LPC Purchase Agreement.

 

The 2022 LPC Purchase Agreement

 

On July 12, 2022, we entered into the 2022 LPC Purchase Agreement with Lincoln Park, which will enhance our balance sheet and financial condition to support our future growth initiatives. As part of the 2022 LPC Purchase Agreement, we issued and sold to Lincoln Par0.70.05 million shares of our common stock as a commitment fee in connection with entering into the 2022 LPC Purchase Agreement with the total value of $0.3 million.  Through September 30,Subsequent to execution of the 2022 LPC Purchase Agreement the Company issued an additional 0.50.43 million shares of common stock to Lincoln Park at an average price of $0.50$4.54 per share, for a total value of $0.3$1.97 million through December 31, 2022. During the six months ended June 30, 2023, the Company issued an additional 0.34 million shares of common stock to Lincoln Park at an average price of $3.23 per share, for a total value of $1.11 million. For additional information regarding the 2022 LPC Purchase Agreement, see Note 14 “Stockholders Equity” in the notes to our unaudited condensed consolidated financial statements included elsewhere in this report.

 

The 2021 Private Placement

On December 15, 2021, the Company consummated the 2021 Private Placement whereby we entered into a securities purchase agreement pursuant to which we issued and sold to the 2021 Investors an aggregate of 653,894 shares of our common stock and 252,717 shares of our Non-Voting Preferred Stock. The gross proceeds from the securities sold in the 2021 Private Placement was $17.0 million. The costs incurred with respect to the 2021 Private Placement totaled $0.3 million and were recorded as a reduction of the 2021 Private Placement proceeds in the consolidated statements of stockholders’ equity. The accounting effects of the 2021 Private Placement transaction are discussed in Note 14 "Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report. These Non-Voting Preferred Stock shares were subsequently converted to common stock upon issuance of the 2022 Private Placement described below.

The 2022 Private Placement

On November 18, 2022, we entered into a securities purchase agreement pursuant to which we issued and sold to the 2022 Investors an aggregate of 116,668 shares of our common stock and 3,185,000 shares of our Voting Preferred Stock. The gross proceeds from the securities sold in the 2022 Private Placement totaled $6.7 million before offering expenses. The costs incurred with respect to the 2022 Private Placement totaled $0.2 million and were recorded as a reduction of the 2022 Private Placement proceeds in the consolidated statements of stockholders’ equity. The accounting effects of the 2022 Private Placement transaction are discussed in Note 14 "Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report.

The 2023 Multi-Tranche Private Placement

In May 2023, we entered into the 2023 Multi-Tranche Private Placement Stock Purchase Agreement with the 2023 Investors pursuant to which the Company may issue and sell to the 2023 Investors up to $9,000,000 in shares of the Senior Preferred Stock in multiple tranches from time to time until December 31, 2025, subject to a minimum aggregate purchase amount of $500,000 in each tranche. The Initial Placement occurred on May 15, 2023, under which the Company sold the 2023 Investors 280,899 shares of Senior Preferred Stock for an aggregate purchase price of $2,000,000. The Company expects to use the proceeds of the Initial Placement, after the payment of transaction expenses, for general working capital purposes. The accounting effects of the 2023 Multi-Tranche Private Placement transaction are discussed in Note 14 "Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report.

Products and Services

 

We derive revenue from the sale of products and services. Product revenue includes revenue from the following:

 

 

the sale, including traditional sales and subscription-based sales, of systems, inclusive of the main console and applicators/handpieces (referred to as system revenue);

 

marketing supplies and kits;

 

consumables and disposables;

 

service revenue; and

 

replacement applicators/handpieces.

 

Service revenue includes revenue derived from our extended warranty service contracts provided to our existing customers and VeroGrafters technician services (which were discontinued in the fourth quarter of 2021).customers.

 

Systems are sold through our subscription model, or through traditional sales contracts directly, through our subscription model, and through distributors. In the third quarter of 2022 we commenced an initiative to reduce our reliance on system sales sold under subscription agreements in the United States. This strategic shift is designed to improve cash generation and reduce our exposure to defaults and increased bad debt expense given the increasingly challenging economic environment caused by the coexistence of high inflation and high interest rates.

 

3426

 

We generate recurring monthly revenue from traditional system sales and from sales under our subscription-based business model, and from traditional system sales. Venus Ltd. commenced a subscription-based modelwhich is available to customers in North America in 2011. Our subscription model is also available in targetedand select international markets in which we operate directly.markets. Approximately 41%30% and 61%49% of our aesthetictotal system revenues were derived from our subscription model in the threesix months ended SeptemberJune 30, 20222023 and 2021, respectively. Approximately 47% and 56% of our aesthetic revenues were derived from our subscription model in the nine months ended September 30, 2022, and 2021, respectively. We currently do not offer the ARTAS iX system under the subscription model. For additional details related to our subscription model, see Item 1. Business Subscription-Based Business Model as filed in our Form 10-K for the year ended December 31, 2021.

Our subscription model includes an up-front fee and a monthly payment schedule, typically over a period of 36 months, with approximately 40% to 45% of total contract payments collected in the first year. To ensure that each monthly payment is made on time and that the customer’s system is serviced in accordance with the terms of the warranty, every product purchased under a subscription agreement requires a monthly activation code, which we provide to the customer upon receipt of the monthly payment. These recurring monthly payments provide our customers with enhanced financial transparency and predictability. If economic circumstances are appropriate, we provide customers in good standing with the opportunity to “upgrade” into our newest available or alternative Venus Concept technology throughout the subscription period. This structure can provide greater flexibility than traditional equipment leases secured through financing companies. We work closely with our customers to provide business recommendations that improve the quality of service outcomes, build patient traffic and improve financial returns for the customer’s business.2022.

 

We have developed and commercialized elevenreceived regulatory clearance for twelve novel aesthetic technology platforms, including our ARTAS and NeoGraft systems. We believe our ARTAS and NeoGraft systems are complementary and give us a hair restoration product offering that can serve a broad segment of the market. Our medical aesthetic technology platforms have received regulatory clearance for a variety of indications, including treatment of facial wrinkles in certain skin types, temporary reduction of appearance of cellulite, non-invasive fat reduction (lipolysis) in the abdomen and flanks for certain body types and relief of minor muscle aches and pains in jurisdictions around the world. In addition, our technology pipeline is focused on the development of robotically assisted minimally invasive solutions for aesthetic procedures that are primarily treated by surgical intervention, including the AI.ME platform for which we received FDA 510(k) clearance for fractional skin resurfacing in December 2022.

 

In the United States, we have obtained 510(k) clearance from the FDA for our Venus Viva, Venus Viva MD, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, Venus Bliss Max, Venus Epileve, Venus Fiore, ARTAS, and ARTAS iX and AI.ME systems. Outside the United States, we market our technologies in over 60 countries across Europe, the Middle East, Africa, Asia-Pacific and Latin America. Because each country has its own regulatory scheme and clearance process, not every device is cleared or authorized for the same indications in each market in which a particular system is marketed.

 

As of SeptemberJune 30, 2022,2023, we operated directly in 1814 international markets through our 1511 direct offices in the United States, Canada, United Kingdom, Japan, South Korea, Mexico, Argentina, Colombia, Spain, France, Germany, Australia, China, Hong Kong, and Israel. 

 

Our revenues for the three months ended SeptemberJune 30, 2023, and 2022 and 2021 were $21.5$20.1 million and $24.6$27.3 million, respectively. Our revenues for the ninesix months ended SeptemberJune 30, 2023, and 2022 and 2021 were $75.2$40.6 million and $73.0$53.7 million, respectively. We had a net loss attributable to Venus Concept of $14.6$7.4 million and $9.8$10.6 million in the three months ended SeptemberJune 30, 2022,2023, and 2021,2022, respectively. We had a net loss attributable to Venus Concept of $33.8$17.0 million and $18.7$19.2 million in the ninesix months ended SeptemberJune 30, 2022,2023, and 2021,2022, respectively. We had an Adjusted EBITDA loss of $7.7$3.9 million and $3.5$5.5 million for the three months ended SeptemberJune 30, 2022,2023, and 2021,2022, respectively. We had an Adjusted EBITDA loss of $19.0$9.7 million and $8.1$11.3 million for the ninesix months ended SeptemberJune 30, 2022,2023, and 2021,2022, respectively.

 

Use of Non-GAAP Financial Measures

 

Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange loss (gain), financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

 

3527

 

We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.

 

The following is a reconciliation of net loss to Adjusted EBITDA for the periods presented:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Reconciliation of net loss to adjusted EBITDA

 

(in thousands)

 

(in thousands)

  

(in thousands)

 

(in thousands)

 

Net loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

Foreign exchange loss

 2,014  1,645  4,389  2,489 

Foreign exchange loss (gain)

 (178) 2,370  (530) 2,375 

(Gain) loss on disposal of subsidiaries

 (1)   76   

Finance expenses

 1,219  1,000  3,176  4,046  1,553  1,034  3,061  1,957 

Income tax (benefit) expense

 (162) 616  92  609 

Income tax expense (benefit)

 189  (18) 424  254 

Depreciation and amortization

 1,081 1,305 3,293 3,756  1,010 1,111 2,032 2,212 

Stock-based compensation expense

 551  536  1,552  1,602  369  558  850  1,001 

Gain on forgiveness of government assistance loans

           (2,775)

Inventory provision (1)

 1,388  1,388  

Other adjustments (2)

  726  188  726  188 

Other adjustments (1)

  412    1,330   

Adjusted EBITDA

 $(7,679) $(3,548) $(19,028) $(8,116) $(3,967) $(5,457) $(9,701) $(11,349)

 

(1) For the three and ninesix months ended SeptemberJune 30, 2022, the inventory provision represents a strategic review of our product offerings which culminated in a decision to discontinue production and sale of certain models and component parts, resulting in an inventory adjustment of $1.4 million.

(2) For the three and nine months ended September 30, 2022,2023, the other adjustments are represented by severance payments associated with a workforce reduction in Venus Spainprimarily represent restructuring activities designed to improve the Company's operations and Venus Canada of $0.7 million. For the three and nine months ended September 30, 2021, the other adjustments are represented by a loss on the sale of a subsidiary in South Africa ($0.2 and $0.2 million, respectively).cost structure.

 

36

Key Factors Impacting Our Results of Operations

 

Our results of operations are impacted by several factors, but we consider the following to be particularly significant to our business:

 

Number of systems delivered. The majority of our revenue is generated from the delivery of systems, both under traditional sales contracts and subscription agreements. The following table sets forth the number of systems we have delivered in the geographic regions indicated:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

United States

 95 122 325 307  135 104 221 230 

International

  255  261  908  838   197  326  434  653 

Total systems delivered

  350   383   1,233   1,145   332   430   655   883 

 

Mix between traditional sales, subscription model sales and distributor sales. We deliver systems through (1) traditional direct system sales contracts to customers, (2) our subscription model, and (3) system sales through distribution agreements. Unit deliveries under direct system sales contracts and subscription agreements have higher per unit revenues and gross margins, while revenues and gross margins on systems sold through distributors are lower. However, distributor sales do not require significant salesselling and marketing support as these expenses are borne by the distributors. In addition, while traditional system sales and subscription agreements have similar gross margins, cash collections on subscription agreements generally occur over a three-year period, with approximately 40% to 45% collected in the first year and the balance collected evenly over the remaining two years of the subscription agreement. In the third quarter of 2022 we commenced an initiative to reduce our reliance on system sales sold under subscription agreements in the United States.subscription. This strategic shift is designed to improve cash generation and reduce our exposure to defaults and increased bad debt expense given the increasingly challenging economic environment caused by the coexistence of high inflation and high interest rates.

 

Investment in Sales, Marketing and Operations. In recent years, we made a strategic decision to penetrate the global market by investing in sales and marketing expenses across all geographic segments. This included the opening of direct offices and hiring experienced sales, marketing, and operational staff. While we generated incremental product sales in these new markets, these revenues and the related margins did not fully offset the startup investments made in certain countries. We are evaluatingcontinue to evaluate our profitability and growth prospects in these countries, post-COVID-19, and have taken and will continue to take steps to exit countries which we do not believe will produce sustainable results. Since June 2020 we have closed 9ceased direct officessales operations in 13 countries across Europe, Asia Pacific, Latin America and Africa and have increased our investment and focus in the United States market.

 

In the three and ninesix months ended SeptemberJune 30, 20222023, and 20212022, respectively, we did not open any direct sales offices.

 

Bad Debt Expense. We maintain an allowance for doubtful accountsexpected credit losses for estimated losses that may primarily arise from subscription customers that are unable to make the remaining payments required under their subscription agreements. During the three and ninesix months ended SeptemberJune 30, 2022,2023, our collections results were negatively impacted by macroeconomic headwinds, including increased interest rates and inflationary factors impacting the operating costs and liquidity positions of our customers. In addition,As a result, we increased the allowance for doubtful accountsexpected credit losses as a percentage of gross outstanding accounts receivable from the period ended SeptemberJune 30, 20212022 to the period ended SeptemberJune 30, 2022.2023. We incurred a bad debt expense of $2.4$0.4 million and $5.9$1.0 million during the three and ninesix months ended SeptemberJune 30, 2022, respectively. We recovered2023. In addition, we continue to focus our selling efforts on cash sales and subscription customers with a bad debt expense of $nil and $2.1 million during the three and nine months ended September 30, 2022 respectively.stronger credit profile. As of SeptemberJune 30, 2022,2023, our allowance for doubtful accounts stands at $13.1expected credit losses was $13.2 million which represents 17.0%21.1% of the gross outstanding accounts receivable as of this date. As of SeptemberJune 30, 2021,2022, our allowance for doubtful accounts stands at $11.5expected credit losses was $14.1 million which represents 13.9%16.1% of the gross outstanding accounts receivable as of this date.

 

3728

 

Outlook

 

While the impact of Covid-19 on our business has largely subsided, we continue to closely monitor all Covid-19 developments  including its impact on our customers, employees, suppliers, vendors, business partners, and distribution channels. In addition, theThe global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases to inflation rates, rising interest rates, foreign currency impacts, declines in consumer confidence, and declines in economic growth. All these factors point to uncertainty about economic stability, and the severity and duration of these conditions on our business cannot be predicted. The momentum and strength in our overall performance demonstrated in the first half of this fiscal year slowed in the three months ended September 30, 2022. The bulk of the thirdsecond quarter revenue decline was due to a strategy shift to prioritize cash deals over subscription deals in order to improve cash generation and preserve liquidity. However, weWe continue to focus on quality of revenue and despite the revenue decline, our cash used in operations was $11.7 million lower than the same period in 2022. We remain focused on adapting to the challenges presented by the current macro economicmacro-economic environment.

 

Supply chain. In the second half of 2021 we were impacted by the global supply disruptions related to COVID-19, which resulted in our inability to fulfil demand for certain of our products. The value of such purchase order backlog in the third and the fourth quarters of 2021 was $2.4 million and $1.0 million, respectively, which was substantially fulfilled during the fourth quarter of 2021 and the first quarter of 2022. We did not experience significant supply issues during the three and ninesix months ended SeptemberJune 30, 20222023 as we continue to actively work with our suppliers and third-party manufacturers to mitigate supply issues and buildmanage inventory of key component parts. WeWhile we have seen recent improvements in global supply chain reliability we anticipate some supply challenges throughout the remainder of 2022,2023, including long production lead times and shortages of certain materials or components that may impact our ability to manufacture the number of systems required to meet customer demand. In addition, since the second quarter of 2021 we have experienced significant inflationary pressures throughout our supply chain, whichchain. While such inflationary pressures have moderated in the first six months of 2023, we expect to continue through the balance of 2022. We expect to mitigate such pressures,any future inflation impacts where possible through price increases and margin management.

 

Global Economic conditions.General global economic downturns and macroeconomic trends, including heightened inflation, capital markets volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, have resulted and may continue to result in unfavorable conditions that negatively affect demand for our products and exacerbate some of the other risks that affect our business, financial condition and results of operations. Both domestic and international markets experienced significant inflationary pressures in fiscal year 2022 and inflation rates in the U.S., as well as in other countries in which we operate, are currently expected to continue at elevated levels for the near-term, impacting our cost of sales as well as selling, general and administrative expenses. In addition, the Federal Reserve in the U.S. and other central banks in various countries have raised, and may again raise, interest rates in response to concerns about inflation. Interest rate increases or other government actions taken to reduce inflation have resulted in recessionary pressures in many parts of the world and has had, and may continue to have, the effect of further increasing economic uncertainty and heightening these risks.

Sales markets. We are a global business, having established a commercial presence in more than 60 countries during our history. While the continued economic recovery in individual countries during the first ninesix months of 20222023 progressed well in most countries in which we operate, we continue to evaluate our direct operations, particularly those outside of North America. The COVID-19 outbreak continuesAs a result, our international revenues declined in the first six months of 2023 as we operated in three fewer direct markets when compared to be fluid, and the extent to which the pandemic will continue to impact our business remains largely uncertain and could continue to be significant for the foreseeable future.same prior year period.

 

Accounts receivable collections. We remain fully focused on reactivating collections with those at-risk accounts that have struggled through the pandemic but show signs of viability. As of SeptemberJune 30, 20222023, our allowance for doubtful accountsexpected credit losses stands at $13.1$13.2 million, which represents 17.0%21.1% of the gross outstanding accounts receivable as of that date. This represents an increasea decrease of $1.1$0.4 million from our December 31, 20212022 allowance for doubtful accountsexpected credit losses balance of $12.0 million.

With the successful rollout$13.6 million, but remains relatively flat as a percentage of COVID-19 vaccines, combined with a relaxation of government restrictions in certain markets we operate in, our collection experience in 2022 improved relative to earlier stages of the pandemic, with collections in our largest subscription markets averaging 85% of our billings in January 2022, 93% in February 2022, 106% in March 2022, 98% in April 2022, 92% in May 2022,96% in June 2022, 89% in July 2022, 90% in August 2022, and 93% in September 2022. We incurred a bad debt expense of $5.9 million in the first nine months of 2022. We will continue our proactive approach to collections of our accounts receivable and will revisit our allowance for doubtful accounts during the next quarter.total receivables.

 

3829

 

Basis of Presentation

 

Revenues

 

We generate revenue from (1) sales of systems through our subscription model, traditional system sales to customers and distributors, (2) other product revenues from the sale of marketing supplies, andARTAS kits, Viva tips, other consumables and (3) service revenue from our extended warranty service contracts provided to existing customers and the sale of our VeroGrafters technician services. VeroGrafters services were discontinued in the fourth quarter of 2021.customers.

 

System Revenue

 

For the three and ninesix months ended SeptemberJune 30, 2022,2023, approximately 41%26% and 47%30%, respectively, of our total system revenues were derived from our subscription model. For the three and ninesix months ended SeptemberJune 30, 2021,2022, approximately 61%51% and 56%49%, respectively, of our system revenues were derived from our subscription model. The relative decrease in subscription revenues in the third quarterfirst half of 20222023 is in line with our strategy to prioritize cash deals over subscription deals in order to improve cash generation and preserve liquidity.

Our subscription model is designed to provide a low barrier to ownership of our systems and includes an up-front fee followed by monthly payments, typically over a 36-month period. The up-front fee serves as a down payment. The significantly reduced up-front financial commitment, coupled with less onerous credit and disclosure requirements, is intended to make our subscription-based sales program more appealing and affordable to customers, including non-traditional providers of aesthetic services such as family practice physicians, general practice physicians, and operators of medical aesthetic spas. For accounting purposes, theseour subscription arrangements are considered to be sales-type finance leases, where the present value of all cash flows to be received under the subscription agreement is recognized as revenue upon shipment to the customer and achievement of the required revenue recognition criteria.

 

For the three and ninesix months ended SeptemberJune 30, 2022,2023, approximately 48%65% and 43%61%, respectively, of our total system revenues were derived from traditional sales. For the three and ninesix months ended SeptemberJune 30, 2021,2022, approximately 27%42% and 34%40%, respectively, of our system revenues were derived from traditional sales. The increased focus on traditional sales is in line with our strategy to prioritize cash deals over subscription deals in order to improve cash generation and preserve liquidity.

 

Customers generally demand higher discounts in connection with these types oftraditional sales. We recognize revenues from products sold to customers based on the following five steps: (1) identification of the contract(s) with the customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the separate performance obligations in the contract; and (5) recognition of revenue when (or as) the entity satisfies a performance obligation.

 

3930

 

We do not grant rights of return or early termination rights to our customers under either our traditional sales or subscription models. These traditional sales are generally made through our sales team in the countries in which the team operates.

 

For the three and ninesix months ended SeptemberJune 30, 2022,2023, approximately 11%9% of our total system revenues were derived from distributor sales. For the three and ninesix months ended SeptemberJune 30, 2021,2022, approximately 12%7% and 10%11%, respectively, of our system revenues were derived from distributor sales. Under the traditional distributor relationship, we do not sell directly to the end customer and, accordingly, achieve a lower overall margin on each system sold compared to our direct sales. These sales are non-refundable, non-returnable and without any rights of price protection or stock rotation. Accordingly, we consider distributors as end customers, orand are accounted for using the sell-in method.

 

Procedure Based Revenue

 

We generate revenue from the harvesting, site making, and implantation procedures performed with our ARTAS system. The harvesting procedure, as the name suggests, is the act of harvesting hair follicles from the patient’s scalp for implantation in the prescribed areas. To perform these procedures, a disposable clinical kit is required. These kits can be large (with an unlimited number of harvests) or small (with a maximum of 1,100 harvests). The customer must place an online order with us for the number and type of kits desired and make a payment. Upon receipt of the order and the related payment, we ship the kit(s), and the customer must scan the barcode on the kit label in order to perform the procedure. Once the kits are exhausted, the customer must purchase additional kits. The site making procedure uses the ARTAS system to create a recipient site (i.e., site making) in the patient’s scalp affected by androgenic alopecia (or male pattern baldness). The site making procedure also requires a disposable site making kit. The site making kits are sold to customers in the same manner as the kits for harvesting procedures. The implantation procedure utilizes the same disposal kit that is used for site making and involves immediately implanting follicles into the created recipient site. The implantation kits are sold to customers in the same manner as the harvesting and site making kits.

 

Other Product Revenue

 

We also generate revenue from our customer base by selling Glide (a cooling/conductive gel which is required for use with many of our systems), marketing supplies and kits, Viva tips, and various consumables and disposables, replacement applicators and handpieces, and ARTAS system training.

 

Service Revenue

 

We generate ancillary revenue from our existing customers by selling additional services including extended warranty service contracts and, formerly through VeroGrafters technician services for hair restoration using our NeoGraft and ARTAS systems. In the fourth quarter of 2021 we discontinued our VeroGrafters technician services in order to focus on higher margin products and services.contracts.

 

Cost of Goods Sold and Gross Profit

 

Cost of goods sold consists primarily of costs associated with manufacturing our different systems, including direct product costs from third-party manufacturers, warehousing and storage costs and fulfillment and supply chain costs inclusive of personnel-related costs (primarily salaries, benefits, incentive compensation and stock-based compensation). Cost of goods sold also includes the cost of upgrades, technology amortization, royalty fees, parts, supplies, and cost of product warranties.

 

Operating Expenses

 

SalesSelling and Marketing.

We currently sell our products and services using direct sales representatives in North America and in select international markets. Our sales costs primarily consist of salaries, commissions, benefits, incentive compensation and stock-based compensation. Costs also include expenses for travel and other promotional and sales-related activities.activities as well as clinical training costs.

 

Our marketing costs primarily consist of salaries, benefits, incentive compensation and stock-based compensation. They also include expenses for travel, trade shows, and other promotional and marketing activities, including direct and online marketing. As the business environment improves, we expect sales and marketing expenses to continue to increase, but at a rate slightly below our rate of revenue growth.

 

General and Administrative.Administrative

Our general and administrative costs primarily consist of expenses associated with our executive, accounting and finance, information technology, legal, regulatory affairs, quality assurance and human resource departments, direct office rent/facilities costs, and intellectual property portfolio.portfolio management. These expenses consist of personnel-related expenses (primarily salaries, benefits, incentive compensation and stock-based compensation) and allocated facilities costs,, audit fees, legal fees, consultants, travel, insurance, and bad debt expense. During the normal course of operations, we may incur bad debt expense on accounts receivable balances that are deemed to be uncollectible.

 

40

Research and Development.Development

Our research and development costs primarily consist of personnel-related costs (primarily salaries, benefits, incentive compensation, and stock-based compensation), material costs, amortization of intangible assets, regulatory affairs, clinical costs, and facilities costs in our Yokneam, Israel and San Jose, California research centers. Our ongoing research and development activities are primarily focused on improving and enhancing our current technologies, products, and services, and on expanding our current product offering with the introduction of new products and expanded indications.

 

We expense all research and development costs in the periods in which they are incurred. We expect our research and development expenses to increase in absolute dollars as we continue to invest in research, clinical studies, regulatory affairs, and development activities, but to decline as a percentage of revenue as our revenue increases over time.

 

Finance Expenses

 

Finance expenses consistsconsist of interest income, interest expense and other banking charges. Interest income consists of interest earned on our cash, cash equivalents and short-term bank deposits. We expect interest income to vary depending on our average investment balances and market interest rates during each reporting period. Interest expense consists of interest on long-term debt and other borrowings. The interest rates on our long-term debt were 6.1%8.22% for the MSLP Loan and 8.0% for the Notes as of SeptemberJune 30, 20222023 and 3.10%7.39% for the MSLP Loan and 8.0% for the Notes as of December 31, 20212022 .
 

Foreign Exchange (Gain) Loss

 

Foreign currency exchange (gain) loss changes reflect foreign exchange gains or losses related to the change in value of assets and liabilities denominated in currencies other than the U.S. dollar.

 

Income Tax Expense

 

We estimate our current and deferred tax liabilities based on current tax laws in the statutory jurisdictions in which we operate. These estimates include judgments about liabilities resulting from temporary differences between assets and liabilities recognized for financial reporting purposes and such amounts recognized for tax purposes. In certain jurisdictions, only the payments invoiced in the current period are subject to tax, but for accounting purposes, the discounted value of the total subscription agreementscontract is reported and tax affected. This results in a deferred tax credit which is settled in the future period when the monthly installment payment is issued and settled with the customer. Since our inception, we have not recorded any tax benefits for the net operating losses we have incurred in each year or for the research and development tax credits we generated in the United States. We believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized.

Income tax expense is recognized based on the actual taxable income or loss incurred during the three and ninesix months ended SeptemberJune 30, 2022.2023.

 

Non-Controlling Interests

 

We have minority shareholders in one jurisdiction in which we have direct operations. For accounting purposes, these minority partners are referred to as non-controlling interests, and we record the non-controlling interests’ share of earnings in our subsidiaries as a separate balance within stockholders’ equity in the consolidated balance sheets and consolidated statements of stockholders’ equity.

 

4131

 

Results of Operations

 

The following tables set forth our consolidated results of operations in U.S. dollars and as a percentage of revenues for the periods indicated:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 

Consolidated Statements of Loss:

 

(dollars in thousands)

 

(dollars in thousands)

  

(dollars in thousands)

 

(dollars in thousands)

 

Revenues:

          

Leases

 $7,193  $12,634  $29,490  $33,958  $4,311 $11,874 $10,072 $22,297 

Products and services

  14,346   11,929   45,721   39,030   15,764  15,392  30,534  31,375 

Total revenue

 21,539  24,563  75,211  72,988  20,075  27,266  40,606  53,672 

Cost of goods sold

  8,166   7,257   25,029   21,731          

Leases

 721 2,761 2,450 5,461 

Products and services

 5,134 5,459 10,237 11,402 
  5,855   8,220   12,687   16,863 

Gross profit

 13,373  17,306  50,182  51,257   14,220   19,046   27,919   36,809 

Operating expenses:

                  

Sales and marketing

  8,094   8,775   27,484   26,743 

Selling and marketing

 8,380 10,523 16,412 21,607 

General and administrative

 14,128  11,990  41,471  31,983  9,633 12,937 20,818 24,409 

Research and development

 2,576  1,930  7,214  6,005  1,965 2,712 4,602 5,355 

Gain on forgiveness of government assistance loans

           (2,775)

Total operating expenses

  24,798   22,695   76,169   61,956   19,978   26,172   41,832   51,371 

Loss from operations

 (11,425) (5,389) (25,987) (10,699)  (5,758)  (7,126)  (13,913)  (14,562)

Other expenses:

          

Foreign exchange loss

 2,014  1,645  4,389  2,489 

Foreign exchange loss (gain)

 (178) 2,370 (530) 2,375 

Finance expenses

 1,219  1,000  3,176  4,046  1,553 1,034 3,061 1,957 

Loss on disposal of subsidiaries

    188    188 

(Gain) loss on disposal of subsidiaries

  (1)    76   

Loss before income taxes

 (14,658) (8,222) (33,552) (17,422) (7,132) (10,530) (16,520) (18,894)

Income tax (benefit) expense

  (162)  616   92   609   189  (18)  424  254 

Net loss

 $(14,496) $(8,838) $(33,644) $(18,031) $(7,321) $(10,512) $(16,944) $(19,148)

Net loss attributable to the Company

  (14,605)  (9,798)  (33,783)  (18,680)

Net loss attributable to stockholders of the Company

  (7,409)  (10,559)  (17,066)  (19,178)

Net income attributable to non-controlling interest

  109   960   139   649  88 47 122 30 

As a % of revenue:

                    

Revenues

 100% 100% 100% 100% 100% 100% 100% 100%

Cost of goods sold

  37.9  29.5  33.3  29.8   29.2  30.1  31.2  31.4 

Gross profit

  62.1  70.5  66.7  70.2  70.8 69.9 68.8 68.6 

Operating expenses:

          

Sales and marketing

 37.6 35.7 36.5 36.6 

Selling and marketing

 41.7 38.6 40.4 40.3 

General and administrative

 65.6 48.8 55.1 43.8  48.0 47.4 51.3 45.5 

Research and development

 12.0 7.9 9.6 8.2   9.8  9.9  11.3  10.0 

Gain on forgiveness of government assistance loans

        (3.8)

Total operating expenses

  115.1  92.4  101.3  84.9   99.5  96.0  103.0  95.7 

Loss from operations

 (53.0) (21.9) (34.6) (14.7) (28.7) (26.1) (34.3) (27.1)

Foreign exchange loss

 9.4 6.7 5.8 3.4 

Foreign exchange loss (gain)

 (0.9) 8.7 (1.3) 4.4 

Finance expenses

  5.7  4.1  4.2  5.5   7.7  3.8  7.5  3.6 

Loss before income taxes

  (68.1)  (33.5)  (44.6)  (23.9) (35.5) (38.6) (40.7) (35.2)

 

4232

 

The following tables set forth our revenue by region and by product type for the periods indicated:

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 
 

(dollars in thousands)

 

(dollars in thousands)

  

(dollars in thousands)

 

(dollars in thousands)

 

Revenues by region:

                    

United States

 $11,774 $12,259 $38,319 $35,345  $9,757  $13,416  $20,498  $26,545 

International

  9,765  12,304  36,892  37,643   10,318   13,850   20,108   27,127 

Total revenue

 $21,539  $24,563  $75,211  $72,988  $20,075  $27,266  $40,606  $53,672 

 

 

Three Months Ended September 30,

  

Nine Months Ended September 30,

  

Three Months Ended June 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2022

  

2021

  

2023

  

2022

  

2023

  

2022

 
 

(dollars in thousands)

 

(dollars in thousands)

  

(dollars in thousands)

 

(dollars in thousands)

 

Revenues by product:

                    

Subscription—Systems

 $7,193  $12,634  $29,490  $33,958  $4,311  $11,874  $10,072  $22,297 

Products—Systems

 10,416  8,022  33,838  26,526  12,313  11,548  23,377  23,422 

Products—Other (1)

 3,125  2,961  9,702  9,330  2,586  3,080  5,533  6,577 

Services (2)

  805   946   2,181   3,174   865   764   1,624   1,376 

Total revenue

 $21,539  $24,563  $75,211  $72,988  $20,075  $27,266  $40,606  $53,672 

 

(1)

Products-Other include ARTAS procedure kits, Viva tips, Glide and other consumables.

(2)

Services include extended warranty salesComparison of the three months ended June 30, 2023 and VeroGrafters technician services. VeroGrafters technician services were discontinued in the fourth quarter of 2021.2022

Comparison of the three months ended September 30, 2022 and 2021

 

Revenues

 

 

Three Months Ended September 30,

         

Three Months Ended June 30,

      
 

2022

  

2021

  

Change

  

2023

  

2022

  

Change

 

(in thousands, except percentages)

 

$

 

% of Total

 

$

 

% of Total

 

$

 

%

  

$

 

% of Total

 

$

 

% of Total

 

$

 

%

 

Revenues:

                          

Subscription—Systems

 $7,193  33.4  $12,634 51.4 $(5,441) (43.1) $4,311  21.5  $11,874 43.5 $(7,563) (63.7)

Products—Systems

 10,416  48.4  8,022 32.6 2,394 29.8  12,313  61.3  11,548 42.4 765 6.6 

Products—Other

 3,125  14.5  2,961 12.1 164 5.5  2,586  12.9  3,080 11.3 (494) (16.0)

Services

  805  3.7   946  3.9  (141)  (14.9)  865  4.3   764  2.8  101  13.2 

Total

 $21,539  

100.0

  $24,563   100.0  $(3,024)  (12.3) $20,075  

100.0

  $27,266   100.0  $(7,191)  (26.4)

 

Total revenue decreased by $3.0$7.2 million, or 12.3%26%, to 21.5$20.1 million for the three months ended SeptemberJune 30, 20222023 from $24.6$27.3 million for the three months ended SeptemberJune 30, 2021.2022. The decrease in revenue is primarily attributed to an initiative to reduce our reliance on system sales sold under subscription agreements.agreements, and lower ARTAS revenues in the quarter. This strategic shift to minimize subscription sales is designed to improve cash generation and reduce our exposure to defaults and increased bad debt expense given the increasingly challenging economic environment caused by the coexistence of high inflation and high interest rates. Our international business was also impacted by negative foreign exchange headwindsthe closure of $0.8 million due to a strengthening U.S. dollar,3 direct offices in the past year, as well as general macroeconomic headwinds that impacted customer access to capital. Despite the reduction in systems sales sold under subscriptions agreements, our cash generation in the thirdsecond quarter of 20222023 improved due to higher system sales sold on a cash basis. 

 

We sold an aggregate of 350332 systems in the three months ended SeptemberJune 30, 20222023 compared to 383430 systems in the three months ended SeptemberJune 30, 2021.2022. The percentage of systems revenue derived from our subscription model was approximately 41%26% and 61%51% during the three months ended SeptemberJune 30, 20222023 and 2021,2022, respectively. The relative decrease in subscription revenues is in line with our strategy to prioritize cash deals over subscription deals in the U.S. market in order to improve cash generation and preserve liquidity. Specific to the U.S. market, systems revenue derived from our subscription model was approximately 18% and 64% during the three months ended June 30, 2023 and 2022, respectively.

 

4333

 

Other product revenue increaseddecreased by $0.2$0.5 million, or 5.5%16%, to $2.6 million in the three months ended June 30, 2023 compared to $3.1 million in the three months ended SeptemberJune 30, 2022 compared to $2.9 million in the three months ended September 30, 2021. The increase was driven by stronger performance on ARTAS kits and other consumables. 

 

Services revenue decreasedincreased by $0.1$0.1 million, or 14.9%13%, to $0.8 million in the three months ended September 30, 2022, compared to $0.9 million in the three months ended SeptemberJune 30, 2021. The decrease was driven by the discontinuation of our VeroGrafters technician services2023, compared to $0.8 million in the fourth quarter of 2021.three months ended June 30, 2022.

 

Cost of Goods Sold and Gross Profit

 

Cost of goods sold increaseddecreased by $0.9$2.3 million, or 13.0%29%, to $5.9 million in the three months ended June 30, 2023, compared to $8.2 million in the three months ended SeptemberJune 30, 2022, compared2022. Gross profit decreased by $4.8 million, or 25%, to $7.3$14.2 million in the three months ended SeptemberJune 30, 2021. Gross profit decreased by $3.9 million, or 22.6%,2023, compared to $13.4$19.0 million in the three months ended SeptemberJune 30, 2022, compared to $17.3 million in the three months ended September 30, 2021.2022. The decrease in gross profit is primarily due to a decrease in revenue in the United States and Internationalinternational markets driven by the strategic decision to deemphasize subscription sales and the macroeconomic headwindsexit from unprofitable direct markets as discussed above. Gross margin was 62.1%70.8% of revenue in the three months ended SeptemberJune 30, 2022,2023, compared to 70.5%69.9% of revenue in the three months ended SeptemberJune 30, 2021.2022. The decreasemarginal increase was primarily due to a $1.4 million write-down of end-of-life devices and parts inventory, and a $0.8 million foreign exchange headwind as a result of most currencies depreciating relative to the U.S. dollar. Adjusting for these factors, our gross margins are slightly above the prior year period.  

Operating expenses

  

Three Months Ended September 30,

         
  

2022

  

2021

  

Change

 

(in thousands, except percentages)

 

$

  

% of Revenues

  

$

  

% of Revenues

  

$

  

%

 

Operating expenses:

                        

Sales and marketing

 $8,094   37.6  $8,775   35.7  $(681)  (7.8)

General and administrative

  14,128  65.6   11,990   48.8   2,138   17.8 

Research and development

  2,576  12.0   1,930   7.9   646   33.5 

Total operating expenses

 $24,798  

115.1

  $22,695   92.4  $2,103   9.3 

Sales and Marketing. Sales and marketing expenses decreased by $0.7 million or 7.8% in the three months ended September 30, 2022lower ARTAS system sales when compared to the three months ended SeptemberJune 30, 2021.2022. ARTAS systems have a slightly lower gross margin than our energy based devices. 

Operating expenses

  

Three Months Ended June 30,

         
  

2023

  

2022

  

Change

 

(in thousands, except percentages)

 

$

  

% of Revenues

  

$

  

% of Revenues

  

$

  

%

 

Operating expenses:

                        

Selling and marketing

 $8,380   41.7  $10,523   38.6  $(2,143)  (20.4)

General and administrative

  9,633  48.0   12,937   47.4   (3,304)  (25.5)

Research and development

  1,965  9.8   2,712   9.9   (747)  (27.5)

Total operating expenses

 $19,978  

99.5

  $26,172   96.0  $(6,194)  (23.7)

Selling and Marketing

Selling and marketing expenses decreased by $2.1 million or 20% in the three months ended June 30, 2023 compared to the three months ended June 30, 2022. This decrease is largely due to lower revenues and reduced marketing expenditures as we consolidate some of these activities. As a percentage of total revenues, our salesselling and marketing expenses increased by 1.9%3.1%, from 35.7%38.6% in the three months ended SeptemberJune 30, 20212022 to 37.6%41.7% in the three months ended SeptemberJune 30, 2022.2023. As the business environment improves, we expect salesselling and marketing expenses to increase in absolute terms, but at a rate slightly below our rate of revenue growth.

 

General and Administrative.

General and administrative expenses increaseddecreased by $2.1$3.3 million or 17.8%26% in the three months ended SeptemberJune 30, 20222023 compared to the three months ended SeptemberJune 30, 2021,2022, primarily due to increased bad debt expense, andexiting certain unprofitable direct markets, partially offset by inflationary pressures associated with salaries and other cost elements. As a percentage of total revenues, our general and administrative expenses increased by 16.8%0.6%, from 48.8%47.4% in the three months ended SeptemberJune 30, 2021,2022, to 65.6%48.0% in the three months ended SeptemberJune 30, 2022,2023, primarily due to the increasesdecrease in costs previously discussed.year over year total revenues. 

 

4434

 

Research and Development.

Research and development expenses increaseddecreased by $0.7 million or 33.5%28% in the three months ended SeptemberJune 30, 20222023 compared to the three months ended SeptemberJune 30, 2021.2022. We experienced significant cost savings through the consolidation of activities between our Israel and United States sites, partially offset by a reinvestment in research and development efforts directed at scaling our robotic technology across other aesthetic platforms. As a percentage of total revenues, our research and development expenses decreased by 0.1%, from 9.9% in the three months ended June 30, 2022, to 9.8% in the three months ended June 30, 2023.

Foreign Exchange (Gain) Loss

We had $0.2 million of foreign exchange gain in the three months ended June 30, 2023 and foreign exchange loss of $2.4 million in the three months ended June 30, 2022. It increased by $2.6 million in the three months ended June 30, 2023 compared to the three months ended June 30, 2022. Changes in foreign exchange are driven mainly by the effect of foreign exchange on accounts receivable balances denominated in currencies other than the US dollar. We do not currently hedge against foreign currency risk.

Finance Expenses

Finance expenses increased by $0.5 million or 50.2%, to $1.6 million in the three months ended June 30, 2023, compared to $1.0 million in the three months ended June 30, 2022, mostly due to an increase in LIBOR rates on our MSLP loan. See “—Liquidity and Capital Resources” below.

Income Tax Expense/Benefit

We had an income tax expense of $0.2 million in the three months ended June 30, 2023 compared to a $0.02 million income tax benefit in the three months ended June 30, 2022. The tax provision is driven by profitable sales and the actual effective tax rates where the sale took place or losses were incurred. In 2023, we had changes in timing of deductible expenses and recognized tax losses in specific judications, which resulted in $0.2 million of income tax expense.

35

Comparison of the six months ended June 30, 2023 and 2022

Revenues

  

Six Months Ended June 30,

         
  

2023

  

2022

  

Change

 

(in thousands, except percentages)

 

$

  

% of Total

  

$

  

% of Total

  

$

  

%

 

Revenues:

                        

Subscription—Systems

 $10,072   24.8  $22,297   41.5  $(12,225)  (54.8)

Products—Systems

  23,377   57.6   23,422   43.6   (45)  (0.2)

Products—Other

  5,533   13.6   6,577   12.3   (1,044)  (15.9)

Services

  1,624   4.0   1,376   2.6   248   18.0 

Total

 $40,606   100.0  $53,672   100.0  $(13,066)  (24.3)

Total revenue decreased by $13.1 million, or 24.3%, to $40.6 million for the six months ended June 30, 2023 from $53.7 million for the six months ended June 30, 2022. The decrease in revenue is primarily attributed to an initiative to reduce our reliance on system sales sold under subscription agreements, and lower ARTAS revenues in the period. This strategic shift to minimize subscription sales is designed to improve cash generation and reduce our exposure to defaults and increased bad debt expense given the increasingly challenging economic environment caused by the coexistence of high inflation and high interest rates. Our international business was also impacted by the closure of 3 direct offices in the past year, as well as general macroeconomic headwinds that impacted customer access to capital. Despite the reduction in systems sales sold under subscriptions agreements, our cash generation in the first half of 2023 improved due to higher system sales sold on a cash basis. 

We sold an aggregate of 655 systems in the six months ended June 30, 2023 compared to 883 systems in the six months ended June 30, 2022. The percentage of systems revenue derived from our subscription model was approximately 30% and 49% during the six months ended June 30, 2023 and 2022, respectively. The relative decrease in subscription revenues is in line with our strategy to prioritize cash deals over subscription deals in the U.S. market in order to improve cash generation and preserve liquidity. Specific to the U.S. market, systems revenue derived from our subscription model was approximately 28% and 49% during the six months ended June 30, 2023 and 2022, respectively.

36

Other product revenue decreased by $1.0 million, or 16%, to $5.5 million in the six months ended June 30, 2023 compared to $6.6 million in the six months ended June 30, 2022. The decrease was primarily driven by lower sales in international markets as we exit unprofitable jurisdictions.

Services revenue increased by $0.2 million, or 18%, to $1.6 million in the six months ended June 30, 2023, compared to $1.4 million in the six months ended June 30, 2022. The increase was driven by higher warranty sales through various chain accounts.

Cost of Goods Sold and Gross Profit

Cost of goods sold decreased by $4.2 million, or 24.9%, to $12.7 million in the six months ended June 30, 2023, compared to $16.9 million in the six months ended June 30, 2022. Gross profit decreased by $8.9 million, or 24.2%, to $27.9 million in the six months ended June 30, 2023, compared to $36.8 million in the six months ended June 30, 2022. The decrease in gross profit is primarily due to a decrease in revenue in the United States and international markets driven by the strategic decision to deemphasize subscription sales and the exit from unprofitable direct markets as discussed above. Gross margin was 68.8% of revenue in the six months ended June 30, 2023, compared to 68.6% of revenue in the six months ended June 30, 2022. The marginal increase was primarily due to lower ARTAS system sales when compared to the six months ended June 30, 2022. ARTAS systems have slightly lower gross margin than our energy based devices.

Operating expenses

  

Six Months Ended June 30,

         
  

2023

  

2022

  

Change

 

(in thousands, except percentages)

 

$

  

% of Revenues

  

$

  

% of Revenues

  

$

  

%

 

Operating expenses:

                        

Selling and marketing

 $16,412   40.4  $21,607   40.3  $(5,195)  (24.0)

General and administrative

  20,818   51.3   24,409   45.5   (3,591) 

(14.7

)

Research and development

  4,602   11.3   5,355   10.0   (753)  (14.1)

Total operating expenses

 $41,832   103.0  $51,371   95.7  $(9,539)  (18.6)

Selling and Marketing

Selling and marketing expenses decreased by $5.2 million or 24% in the six months ended June 30, 2023 compared to the six months ended June 30, 2022. This decrease is largely due to lower revenues and reduced marketing expenditures as we consolidate some of these activities. As a percentage of total revenues, our selling and marketing expenses increased by 0.1%, from 40.3% in the six months ended June 30, 2022 to 40.4% in the six months ended June 30, 2023. As the business environment improves, we expect selling and marketing expenses to increase in absolute terms, but at a rate slightly below our rate of revenue growth.

General and Administrative

General and administrative expenses decreased by $3.6 million or 15% in the six months ended June 30, 2023 compared to the six months ended June 30, 2022, primarily due to exiting certain unprofitable direct markets, partially offset by inflationary pressures associated with salaries and other cost elements. As a percentage of total revenues, our general and administrative expenses increased by 5.8%, from 45.5% in the six months ended June 30, 2022, to 51.3% in the six months ended June 30, 2023, primarily due to the increases in costs noted above. 

37

Research and Development

Research and development expenses decreased by $0.8 million or 14% in the six months ended June 30, 2023 compared to the six months ended June 30, 2022. We experienced some cost savings through the consolidation of activities between our Israel and San Jose sites, partially offset by a reinvestment in research and development efforts directed at scaling our robotic technology across other aesthetic platforms. As a percentage of total revenues, our research and development expenses increased by 4.1%1.3%, from 7.9%10.0% in the threesix months ended SeptemberJune 30, 2021,2022, to 12.0%11.3% in the threesix months ended SeptemberJune 30, 2022.2023.

 

Gain on forgiveness of government assistance loans.Foreign Exchange (Gain) Loss In 2021, we applied for and received partial forgiveness of the PPP Loans with the SBA in the aggregate amount of $2.8 million of original PPP Loans as of September 30, 2021.

 

Foreign exchange loss.We had $2.0$0.6 million of foreign exchange lossgain in the threesix months ended SeptemberJune 30, 20222023 and foreign exchange loss of $1.6$2.4 million in the threesix months ended SeptemberJune 30, 2021. It increased by $0.4 million in the three months ended September 30, 2022 compared to the three months ended September 30, 2021.2022. Changes in foreign exchange are driven mainly by the effect of foreign exchange on accounts receivable balances denominated in currencies other than the US dollar. In the threesix months ended SeptemberJune 30, 2022,2023, most currencies depreciatedappreciated relative to the U.S. dollar. We do not currently hedge against foreign currency risk.

 

Finance Expenses.

Finance expenses increased by $0.2$1.1 million or 20.0%56.4%, from $1.0$2.0 million in the threesix months ended SeptemberJune 30, 2021,2022, compared to $1.2$3.1 million in the threesix months ended SeptemberJune 30, 2022,2023, mostly due to an increase in LIBOR rates on the variable portion of our MSLP loan. See “—Liquidity and Capital Resources” below.

 

Loss on disposal of subsidiariesIncome Tax Expense. During the three months ended September 30, 2021 we sold our 80% share in our subsidiary, Venus Concept Africa (Pty) Ltd., to a non-controlling shareholder for a nominal cash consideration. The disposal resulted in a loss of approximately $0.2 million. 

 

Income Tax Benefit.We had an income tax benefitexpense of $0.2$0.4 million in the threesix months ended SeptemberJune 30, 20222023 compared to $0.6$0.3 million of income tax expense in the threesix months ended SeptemberJune 30, 2021.2022. The tax provision is driven by profitable sales and the actual effective tax rates where the sale took place or losses were incurred. In 2022,2023, we had changes in timing of deductible expenses and taxable income in specific jurisdictions,judications, which resulted in $0.7$0.4 million of income tax benefit.expense.

 

4538

 

Comparison of the nine months ended September 30, 2022 and 2021

Revenues

  

Nine Months Ended September 30,

         
  

2022

  

2021

  

Change

 

(in thousands, except percentages)

 

$

  

% of Total

  

$

  

% of Total

  

$

  

%

 

Revenues:

                        

Subscription—Systems

 $29,490   39.2  $33,958   46.5  $(4,468)  (13.2)

Products—Systems

  33,838   45.0   26,526   36.4   7,312   27.6 

Products—Other

  9,702   12.9   9,330   12.8   372   4.0 

Services

  2,181   2.9   3,174   4.3   (993)  (31.3)

Total

 $75,211   100.0  $72,988   100.0  $2,223   3.0 

Total revenue increased by $2.2 million, or 3.0%, to $75.2 million for the nine months ended September 30, 2022 from $73.0 million for the nine months ended September 30, 2021. The increase in revenue is attributable to a strong performance in the United States where our reinvestment efforts are beginning to yield positive results. Our international markets were lower due to significant foreign exchange headwinds of $1.8 million, partially offset by a strong performance in distributor sales. In the nine months ended September 30, 2022 our hair restoration business led by ARTAS continued to perform well globally, and in the United States we successfully executed a launch of Bliss Max and we expect this to be a key growth driver during the balance of 2022 given its unique coverage of three modalities (fat reduction, skin tightening and muscle stimulation). 

We sold an aggregate of 1,233 systems in the nine months ended September 30, 2022 compared to 1,145 systems in the nine months ended September 30, 2021. The percentage of systems revenue derived from our subscription model was approximately 46.6% and 56% during the nine months ended September 30, 2022 and 2021, respectively. The relative decrease in system revenues sold under subscription is in line with our strategy to prioritize cash deals over subscription deals in order to improve cash generation and preserve liquidity.

46

Other product revenue increased by 0.4 million, or 4.0%, to $9.7 million in the nine months ended September 30, 2022 compared to $9.3 million in the nine months ended September 30, 2021. The increase was driven by stronger performance on ARTAS kits, Venus Viva tips and other consumables.

Services revenue decreased by $1.0 million, or 31.3%, to $2.2 million in the nine months ended September 30, 2022, compared to $3.2 million in the nine months ended September 30, 2021. The decrease was driven by the discontinuation of our VeroGrafters technician services in the fourth quarter of 2021.

Cost of Goods Sold and Gross Profit

Cost of goods sold increased by $3.3 million, or 15.0%, to 25.0 million in the nine months ended September 30, 2022, compared to $21.7 million in the nine months ended September 30, 2021. Gross profit decreased by $1.1 million, or 2.1%, to $50.2 million in the nine months ended September 30, 2022, compared to $51.3 million in the nine months ended September 30, 2021. The decrease in gross profit is primarily attributable to a $1.4 million write-down of end-of-life devices and parts inventory, and foreign exchange headwinds of $1.8 million. Gross margin was 66.7% of revenue in the nine months ended September 30, 2022, compared to 70.2% of revenue in the nine months ended September 30, 2021. The decrease was due to inventory write-downs and foreign exchange impacts noted above. Adjusting for these factors, gross profit is above the prior year period and gross margins are in line with the prior year period.

Operating expenses

  

Nine Months Ended September 30,

         
  

2022

  

2021

  

Change

 

(in thousands, except percentages)

 

$

  

% of Revenues

  

$

  

% of Revenues

  

$

  

%

 

Operating expenses:

                        

Sales and marketing

 $27,484   36.5  $26,743   36.6  $741   2.8 

General and administrative

  41,471   55.1   31,983   43.8   9,488   29.7 

Research and development

  7,214   9.6   6,005   8.2   1,209   20.1 

Gain on forgiveness of government assistance loans

        (2,775)  (3.8)  2,775   (100.0)

Total operating expenses

 $76,169   101.3  $61,956   84.9  $14,213   22.9 

Sales and Marketing. Sales and marketing expenses increased by $0.7 million or 2.8% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. This increase is largely due to our increased focus in the United States, reinvestment in key markets that benefited from the global economic recovery and inflationary pressures associated with salaries and other sales and marketing cost elements. As a percentage of total revenues, our sales and marketing expenses decreased by 0.1%, from 36.6% in the nine months ended September 30, 2021 to 36.5% in the nine months ended September 30, 2022. As the business environment improves, we expect sales and marketing expenses to continue to increase in absolute terms, but at a rate slightly below our rate of revenue growth.

General and Administrative. General and administrative expenses increased by $9.5 million or 29.7% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, primarily due to bad debt expense of $5.9 million, whereas in the nine months ended September 30, 2021, we recorded a significant bad debt recovery of $3.2 million due to a reactivation of accounts impacted by COVID-19. General and administrative expenses were also impacted significant inflationary pressures associated with salaries and other cost elements. As a percentage of total revenues, our general and administrative expenses increased by 11.3%, from 43.8% in the nine months ended September 30, 2021, to 55.1% in the nine months ended September 30, 2022, primarily due to the increases in costs noted above. 

47

Research and Development. Research and development expenses increased by $1.2 million or 20.1% in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. The increase is due to a reinvestment in research and development efforts directed at scaling our robotic technology across other aesthetic platforms. As a percentage of total revenues, our research and development expenses increased 1.4%, from 8.2% in the nine months ended September 30, 2021, to 9.6% in the nine months ended September 30, 2022.

Gain on forgiveness of government assistance loans. In 2021, we applied for and received partial forgiveness of the PPP Loans with the SBA in the aggregate amount of $2.8 million of original PPP Loans as of September 30, 2021.

Foreign exchange loss. We had $4.4 million of foreign exchange loss in the nine months ended September 30, 2022 and foreign exchange loss of $2.5 million in the nine months ended September 30, 2021. It increased by $1.9 million in the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021. Changes in foreign exchange are driven mainly by the effect of foreign exchange on accounts receivable balances denominated in currencies other than the US dollar. In the nine months ended September 30, 2022, most currencies depreciated relative to the U.S. dollar. We do not currently hedge against foreign currency risk.

Finance Expenses. Finance expenses decreased by $0.8 million or 20.9%, from $4.0 million in the nine months ended September 30, 2021, compared to $3.2 million in the nine months ended September 30, 2022, mostly due to decreased amortization of deferred finance costs, paritally offset by higher LIBOR rates on our MSLP loan. See “—Liquidity and Capital Resources” below.

Loss on disposal of subsidiaries. During the nine months ended September 30, 2021 we sold our 80% share in our subsidiary, Venus Concept Africa (Pty) Ltd., to a non-controlling shareholder for a nominal cash consideration. The disposal resulted in a loss of approximately $0.2 million. 

Income Tax Expense. We had an income tax expense was $0.1 million in the nine months ended September 30, 2022 compared to $0.6 million of income tax expense in the nine months ended September 30, 2021. The tax provision is driven by profitable sales and the actual effective tax rates where the sale took place or losses were incurred. In the first nine months of 2022, we had changes in timing of deductible expenses and taxable income in specific jurisdictions, which resulted in $1.2 million of income tax benefit.

48

Liquidity and Capital Resources

 

We had $6.8$6.1 million and $30.9$11.6 million of cash and cash equivalents as of SeptemberJune 30, 2022,2023, and December 31, 2021,2022, respectively. We have funded our operations with cash generated from operating activities, through the sale of equity securities and through debt financing. We had total debt obligations of approximately $77.6$78.4 million as of SeptemberJune 30, 2022,2023, including the MSLP Loan of $50.9$51.2 million, and convertible notes of $26.7 million including closing fees of $1.6$27.2 million, compared to total debt obligations of approximately $77.8$77.7 million as of December 31, 2021.2022.

 

Our working capital requirements reflect the growth of our business over the last few years. Working capital is primarily impacted by growth in our subscription sales which also impacts accounts receivable. Our overall growthrecent shift to prioritize traditional cash sales over subscription sales is designed to improve liquidity and reduce working capital requirements over time. Our expanding product portfolio also requires higher inventory levels to meet demand and to accommodate the increased number of technology platforms offered. We had a split of subscription sales revenue to traditional sales revenue at a ratio of approximately 52:4830:70 in the ninesix months ended SeptemberJune 30, 2022,2023, compared to 56:4455:45 in the ninesix months ended SeptemberJune 30, 2021.2022. We expect a slight increase in the ratio of traditional sales to subscription sales in 2023 and beyond. We expect inventory to continue to increaseremain relatively flat in the short term but increase at a lower rate than the rate of revenue growth.growth over the longer term.

 

We also require modest funding for capital expenditures. Our capital expenditures relate primarily to our research and development facilities in Yokneam, Israel and San Jose, California. In addition, our past capital investments have included improvements and expansion of our subsidiaries’ operations to support our growth.growth, but do not expect to incur such costs over the next twelve months.

 

Issuance of Secured Subordinated Convertible Notes

 

Contemporaneously with the MSLP Loan Agreement, on December 9, 2020, we issued $26.7 million aggregate principal amount of the Notes to the Madryn Noteholders pursuant to the terms of the Exchange Agreement. The Notes will accrue interest at a rate of 8.0% per annum from the date of original issuance of the Notes to the third anniversary date of the original issuance and thereafter interest will accrue at a rate of 6.0% per annum. In connection with the Exchange Agreement, we also entered into (i) the Madryn Security Agreement, pursuant to which we agreed to grant Madryn a security interest, in substantially all of our assets, to secure the obligations under the Notes and (ii) the CNB Subordination Agreement. The Notes are convertible at any time into shares of our common stock at an initial conversion price of $3.25$48.75 per share, subject to adjustment. For additional information regarding the Notes, Exchange Agreement, Madryn Security Agreement and CNB Subordination Agreement, see Note 1011 “Madryn Long-Term Debt and Convertible Notes” to our unaudited condensed consolidated financial statements included elsewhere in this report.

 

Main Street Priority Lending Program Term Loan

 

On December 8, 2020, we executed the MSLP Loan Agreement, MSLP Note, and related documents for a loan in the aggregate amount of $50.0 million for which CNB will serve as a lender pursuant to the Main Street Priority Loan Facility as established by the Board of Governors of the Federal Reserve System Section 13(3) of the Federal Reserve Act. For additional information regarding this loan, see Note 910 “Main Street Term Loan” to our unaudited condensed consolidated financial statements included elsewhere in this report.

 

CNB Loan Agreement

 

We have a revolving credit facility with CNB pursuant to which CNB agreed to provide a revolving credit facility to us and certain of our subsidiaries to be used to finance working capital requirements. As of December 31, 2020, a portion of the proceeds from the MSLP Loan described above was used to repay $3.2 million of outstanding borrowings under the CNB Loan Agreement. There was $nil outstanding balance as of SeptemberJune 30, 20222023 and December 31, 2021. 2022. On February 22, 2023, CNB notified the Company that it would be temporarily restricting advances under the Fourth Amended and Restated CNB Loan Agreement pursuant to its rights under Section 2 of the agreement. CNB and the Company continue to actively discuss lifting the restrictions on advances under the credit facility.

 

On August 26, 2021 we entered into the Fourth Amended and Restated CNB Loan Agreement with CNB, pursuant to which, among other things, (i) the maximum principal amount the revolving credit facility was reduced from $10.0 million to $5.0 million at the LIBOR 30-Day rate plus 3.25%, subject to a minimum LIBOR rate floor of 0.50%, and (ii) beginning December 10, 2021, the cash deposit requirement was reduced from $3.0 million to $1.5 million, to be maintained with CNB at all times during the term of the Amended CNB Loan Agreement. As of SeptemberJune 30, 2022,2023, and December 31, 2021,2022, we were in compliance with all required covenants. For additional information on the CNB Loan Agreement and the related agreements, see Note 1112 “Credit Facility” to our unaudited condensed consolidated financial statements included elsewhere in this report.

 

4939

 

Equity Purchase Agreement with Lincoln Park

 

On June 16, 2020, we entered into the Equity Purchase Agreement with Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we may sell to Lincoln Park up to $31.0 million of shares of our common stock pursuant to our shelf registration statement. The purchase price of shares of common stock related to a future sale will be based on the then prevailing market prices of such shares at the time of sales as described in the Equity Purchase Agreement. The aggregate number of shares that we can sell to Lincoln Park under the Equity Purchase Agreement may in no case exceed the Exchange Cap, unless (i) stockholder approval is obtained to issue shares above the Exchange Cap, in which case the Exchange Cap will no longer apply, or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Equity Purchase Agreement equals or exceeds $3.9755$59.6325 per share (subject to adjustment) (which represents the minimum price, as defined under Nasdaq Listing Rule 5635(d), on the Nasdaq Global Market immediately preceding the signing of the Equity Purchase Agreement, such that the transactions contemplated by the Equity Purchase Agreement are exempt from the Exchange Cap limitation under applicable Nasdaq rules). Also, at no time may Lincoln Park (together with its affiliates) beneficially own more than 9.99% of our issued and outstanding common stock. Concurrently with entering into the Equity Purchase Agreement, we also entered into a Registration Rights AgreementAgreement with Lincoln Park (as defined above).

 

In

During the nine monthsyear ended September 30,December 31, 2022, we issued and sold 0.40.03 million shares of our common stock shares to Lincoln Park under the Equity Purchase Agreement,. at which point this agreement expired. The net cash proceeds from shares issuance as of September 30,December 31, 2022 were $0.3 million. The Equity Purchase Agreement expired on July 1, 2022,2022 and was subsequently replaced by the 2022 LPC Purchase Agreement.

The 2021 Private Placement


On December 15, 2021, the Company consummated the 2021 Private Placement whereby entered into a securities purchase agreement pursuant to which we issued and sold to the 2021 Investors an aggregate of 653,894 shares of our common stock and 252,717 shares of our Non-Voting Preferred Stock. The gross proceeds from the securities sold in the 2021 Private Placement was $17.0 million. The costs incurred with respect to the 2021 Private Placement totaled $0.3 million and were recorded as a reduction of the 2021 Private Placement proceeds in the consolidated statements of stockholders’ equity. The accounting effects of the 2021 Private Placement transaction are discussed in Note 14 "
Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report. These Non-Voting Preferred Stock shares were subsequently converted to common stock upon issuance of the 2022 Private Placement described below.

 

The 2022 LPC Purchase Agreement

 

On July 12, 2022, we entered into the 2022 LPC Purchase Agreement with Lincoln Park, and we issued and sold to Lincoln Par0.70.05 million shares of our common stock as a commitment fee in connection with entering into the 2022 LPC Purchase Agreement, with the total value of $0.3 million. Through SeptemberJune 30, 2023 we issued an additional 0.50.78 million shares of common stock to Lincoln Park at an average price of $0.50$3.97 per share, for a total proceeds value of $0.3 million.$3.1 million since entering into the Purchase Agreement. For additional information regarding the 2022 LPC Purchase Agreement, see Note 14 “Stockholders Equity” in the notes to our unaudited condensed consolidated financial statements included elsewhere in this report.

 

The 2022 Private Placement

On November 18, 2022, we consummated the 2022 Private Placement whereby we entered into a securities purchase agreement pursuant to which we issued and sold to the 2022 Investors an aggregate of 116,668 shares of our common stock and 3,185,000 shares of our Voting Preferred Stock. The gross proceeds from the securities sold in the 2022 Private Placement totaled $6.7 million before offering expenses. The costs incurred with respect to the 2022 Private Placement totaled $0.2 million and were recorded as a reduction of the 2022 Private Placement proceeds in the consolidated statements of stockholders’ equity. The accounting effects of the 2022 Private Placement transaction are discussed in Note 14 "Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report.

The 2023 Multi-Tranche Private Placement

In May 2023, we entered into the 2023 Multi-Tranche Private Placement Stock Purchase Agreement, with the 2023 Investors pursuant to which the Company may issue and sell to the 2023 Investors up to $9,000,000 in shares of Senior Preferred Stock, in multiple tranches from time to time until December 31, 2025, subject to a minimum aggregate purchase amount of $500,000 in each tranche. The Initial Placement occurred on May 15, 2023, under which the Company sold the 2023 Investors 280,899 shares of Senior Preferred Stock for an aggregate purchase price of $2,000,000. The Company expects to use the proceeds of the Initial Placement, after the payment of transaction expenses, for general working capital purposes. The accounting effects of the 2023 Multi-Tranche Private Placement transaction are discussed in Note 14 "Stockholders Equity" in the notes to our consolidated financial statements included elsewhere in this report. 

5040

 

Government Assistance Programs

In April 2020, Venus Concept Inc. and Venus USA, received funding in the total amount of $4.1 million, in connection with two “Small Business Loans” under the PPP.

We borrowed $1.7 million pursuant to the Venus Concept PPP Loan. Venus USA also borrowed $2.4 million pursuant to the Venus USA PPP Loan. The terms of the Venus USA PPP Loan are substantially similar to the terms of the Venus Concept PPP Loan. In 2021, we applied through CNB, for partial forgiveness of both PPP Loans with the SBA and received partial forgiveness of the Venus USA PPP Loan in the amount of $1.7 million and the Venus Concept PPP Loan in the amount of $1.1 million. The remaining portion of the PPP Loans of the Company was fully repaid in the nine months ended September 30, 2022. 

In 2020, certain subsidiaries also received funding in the total amount of $1.1 million in connection with various governmental programs to support businesses impacted by COVID-19. The terms of these government assistance programs vary by jurisdiction. These government subsidies were recorded as a reduction to the associated wage costs recorded in general and administrative expenses in the unaudited condensed consolidated statement of operations.

For additional information on our utilization of government assistance programs, see Note 12 “Government Assistance Programs” in the notes to our unaudited condensed consolidated financial statements included elsewhere in this report.

Capital Resources

 

As of SeptemberJune 30, 2022,2023, we had capital resources consisting of cash and cash equivalents of approximately $6.8$6.1 million. We have financed our operations principally through the issuance and sale of our common stock and preferred stock, debt financing, and payments from customers.

 

We believe that the net proceeds from the 2023 Multi-Tranche Private Placement, the 2022 Private Placement, the 2021 Private Placement, net proceeds from the December 2020 Public Offering, the proceeds from issuance of our common stock to Lincoln Park, the proceeds from the government assistance programs, the proceeds from the MSLP Loan, our continued availability under the 2022 LPC Purchase Agreement, our strategic cash flow enhancement initiatives, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We cannot assure youcan provide no assurances that we will be successful in raising additional capital or that such capital, if available at all, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to reduce the scope of our operations and planned capital or research and development expenditures or sell certain assets, including intellectual property assets.

51

 

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:

 

 

delay or curtail our efforts to develop system product enhancements or new products, including any clinical trials that may be required to market such enhancements;

 

delay or curtail our plans to increase and expand our sales and marketing efforts; or

 

delay or curtail our plans to enhance our customer support and marketing activities.

 

We are restricted by covenants in the MSLP Loan, the Amended CNB Loan Agreement, and the Madryn Security Agreement and other government assistance programs.Agreement. These covenants restrict, among other things, our ability to incur additional indebtedness, which may limit our ability to obtain additional debt financing. In the event that the pandemic and the economic disruptions it has caused continue for an extended period of time, we cannot assure you that we will remain in compliance with the financial covenants contained in our credit facilities. We also cannot assure you that our lenders would provide relief or that we could secure alternative financing on favorable terms, if at all. Our failure to comply with the covenants contained in our credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.

 

We have based our projections on the amount of time through which our financial resources will be adequate to support our operations on assumptions that may prove to be incorrect, and we may use all our available capital resources sooner than we expect. Our future funding requirements, including long-term funding requirements, will depend on many factors, including, but not limited to:

 

 

the cost of growing our ongoing commercialization and sales and marketing activities;

 

the costs of manufacturing and maintaining enough inventories of our systems to meet anticipated demand and inventory write-offs related to obsolete products or components;

 

the costs of enhancing the existing functionality and development of new functionalities for our systems;

 

the costs of preparing, filing, prosecuting, defending, and enforcing patent claims and other patent related costs, including litigation costs and the results of such litigation;

 

the variability of ARTAS procedures being performed between periods if particular high-volume practitioners perform a smaller number of procedures in each period as a result of the concentration of procedures performed by certain practitioners;

any product liability or other lawsuits and the costs associated with defending them or the results of such lawsuits;

 

the costs associated with conducting business and maintaining subsidiaries and other entities in foreign jurisdictions;

 

customers in jurisdictions where our systems are not approved delaying their purchase, and not purchasing our systems, until they are approved or cleared for use in their market;

 

the costs to attract and retain personnel with the skills required for effective operations; and

 

the costs associated with being a public company; and

uncertainties related to the COVID-19 pandemic and related variants.company.

 

In order to grow our business and increase revenues, we will need to introduce and commercialize new products, grow our sales and marketing force, implement new software systems, as well as identify and penetrate new markets. Such endeavors have in the past increased, and may continue in the future, to increase our expenses, including sales and marketing, and research and development. We will have to continue to increase our revenues while effectively managing our expenses in order to achieve profitability and to sustain it. Our failure to control expenses could make it difficult to achieve profitability or to sustain profitability in the future. Moreover, we cannot be sure that our expenditures will result in the successful development and introduction of new products in a cost-effective and timely manner or that any such new products will achieve market acceptance and generate revenues for our business.

 

5241

 

Cash flows

 

The following table summarizes our cash flows for the periods indicated:

 

 

Nine Months Ended September 30,

  

Six Months Ended June 30,

 
 

2022

  

2021

  

2023

  

2022

 
 

(in thousands)

  

(in thousands)

 

Cash used in operating activities

 $(23,573) $(19,370) $(8,010) $(19,713)

Cash used in investing activities

 

(297

) (234) 

(92

) (251)

Cash (used in) provided by financing activities

 

(229

)  1,088  

2,655

   (372)

Net decrease in cash and cash equivalents

 $(24,099) $(18,516) $(5,447) $(20,336)

 

Cash Flows from Operating Activities

 

For the ninesix months ended SeptemberJune 30, 2023, cash used in operating activities consisted of a net loss of $16.9 million, partially offset by a decrease in net operating assets of $3.8 million and non-cash operating expenses of $5.1 million. The use of cash in net operating assets was attributable to a decrease in accounts receivable of $6.1 million, a decrease in inventories of $0.6 million, a decrease in other current assets of $1.6 million, a decrease in operating right-of-use assets, net of $0.6 million, and an increase in trade payables of $0.3. These were offset by a decrease in accrued expenses and other current liabilities of $4.2 million. The non-cash operating expenses consisted of provision for expected credit losses of $1 million, depreciation and amortization of $2.0 million, finance expenses and accretion of $0.7 million, stock-based compensation expense of $0.9 million, provision for inventory obsolescence of $0.7 million, partially offset by a deferred tax recovery of $0.1 million.

For the six months ended June 30, 2022, cash used in operating activities consisted of a net loss of $33.6$19.1 million and an investment in net operating assets of $2.2$8.1 million, partially offset by non-cash operating expenses of $12.3$7.5 million. The investment in net operating assets was attributable to an increase in accounts receivable of $4.5$2.5 million, a decrease in inventories of $2.7 million, an increase in prepaid expensesadvances to suppliers of 0.8$3.8 million, an increase in other current assets of $0.4$0.1 million, an increase in other long-term assets of $0.3 million, a decrease in trade payables of $1.2 million, and a decrease of severance pay funds of $0.1 million. This was partially offset by a a decrease in inventories of $5.5 million, a decrease in advances to suppliers of $1.4 million, a decrease in accrued expenses and other current liabilities of $2.2 million, a decrease in unearned interest income of $0.1 million, and a decrease in other long-term liabilities of $0.3 million. The non-cash operating expenses consisted of provision for bad debts of $5.9 million, depreciation and amortization of $3.3 million, finance expenses and accretion of $0.3 million, stock-based compensation expense of $1.6 million, provision for inventory obsolescence of $1.8 million, partially offset by a deferred tax recovery of $0.6 million.

For the nine months ended September 30, 2021, cash used in operating activities consisted of a net loss of $18.0 million and an investment in net operating assets of $4.9 million, partially offset by non-cash operating expenses of $3.6 million. The investment in net operating assets was primarily attributable to an increase in inventories of $4.4 million, an increase in advances to suppliers of $0.1 million, an increase in prepaid expensestrade payables of $2.4 million, an increase in other current assets of $0.1 million, an increase in other long-term assets of $0.1 million, a decrease in accounts payabletrade payables of $1.6$0.7 million, a decrease in accrued expenses and other current liabilities of $3.1 million, a decrease in severance pay funds of $0.1$2.0 million, and a decrease in other non-currentlong-term liabilities of $0.1$0.2 million. This was partially offset by a decrease in accounts receivableprepaid expenses of $3.5$0.6 million primarily due to stronger collections as customers start to recover from the pandemic globally during 2021, a decrease in other current assets of $0.9 million and an increase in unearned interest income of $0.1$0.3 million. The non-cash operating expenses consisted mainly of a recoveryprovision for bad debts of $0.6$3.5 million, depreciation and amortization of $3.8$2.2 million, finance expenses and accretion of $1.0$0.2 million, stock-based compensation expense of $1.6$1.0 million, provision for inventory obsolescence of $1.1$0.9 million, loss on the sale ofpartially offset by a subsidiary of $0.2 million, gain on forgiveness of government assistance loans of $2.8 million and deferred tax recovery of $0.7$0.3 million.

 

Cash Flows from Investing Activities

 

In the ninesix months ended SeptemberJune 30, 2023, cash used in investing activities consisted of $0.1 million for the purchase of property and equipment. 

In the six months ended June 30, 2022, cash used in investing activities consisted of $0.3 million for the purchase of property and equipment.

 

In the nine months ended September 30, 2021, cash used in investing activities consisted of $0.2 million for the purchase of property and equipment and the proceeds from the sale of a subsidiary, net of $40 thousand of cash relinquished.

Cash Flows from Financing Activities

 

In the ninesix months ended SeptemberJune 30, 2023, cash used in financing activities primarily consisted of net proceeds from the issuance of shares of common stock to Lincoln Park of $1.1 million and net proceeds from the 2023 Multi-Tranche Private Placement of $1.6 million. 

In the six months ended June 30, 2022, cash used in financing activities primarily consisted of net proceeds from the issuance of shares of common stock to Lincoln Park of $0.3 million, proceeds from exercise of options of $23 thousand, offset by a $0.6 million repayment of government assistance loans and $0.1 million of dividends from subsidiaries paid to non-controlling interest, partially offset by net proceeds from the issuance of shares of common stock to Lincoln Park of $0.4 million and proceeds from exercise of options of $23 thousand. interest.

In the nine months ended September 30, 2021, cash provided by financing activities consisted primarily of proceeds from the exercise of 2020 December Public Offering Warrants of $0.9 million, proceeds from the exercise of options of $0.3 million, partially offset by the payment of the NeoGraft earn-out liability of $0.1 million..

 

5342

 

Contractual Obligations and Other Commitments

 

Our premises are leased under various operating lease agreements, which expire on various dates.

 

As of SeptemberJune 30, 2022,2023, we had non-cancellable purchase orders placed with our contract manufacturers in the amount of $16.5$15.1 million. In addition, as of SeptemberJune 30, 2022,2023, we had $5.1$0.7 million of open purchase orders that can be cancelled with 270 days’ notice, except for a portion equal to 25% of the total amount representing the purchase of “long lead items”.items."

 

The following table summarizes our contractual obligations as of SeptemberJune 30, 2022,2023, which represent material expected or contractually committed future obligations.

  

Payments Due by Period

 
  

Less than 1 Year

  

2 to 3 Years

  

4 to 5 Years

  

More than 5 Years

  

Total

 
  

(in thousands)

 

Debt obligations, including interest

 $5,358  $22,947  $64,840  $  $93,145 

Operating leases

  2,098   2,828   1,888   583   7,397 

Purchase commitments

  17,785            17,785 

Total contractual obligations

 $25,241  $25,775  $66,728  $583  $118,327 

On March 25, 2021, we entered into an endorsement agreement for the services of Venus Williams, four-time Olympic Gold Medalist, seven-time Grand Slam Champion and entrepreneur, pursuant to which Ms. Williams will act as a brand ambassador for Venus Bliss. The endorsement agreement expired on November 1, 2022.

  

Payments Due by Period

 
  

Less than 1 Year

  

2 to 3 Years

  

4 to 5 Years

  

More than 5 Years

  

Total

 
  

(in thousands)

 

Debt obligations, including interest

 $14,139  $77,807  $  $  $91,946 

Operating leases

  1,679   2,158   1,038   544   5,419 

Purchase commitments

  15,086            15,086 

Total contractual obligations

 $30,904  $79,965  $1,038  $544  $112,451 

 

For an additional description of our commitments see Note 8,9, “Commitments and Contingencies” to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

54

Off-Balance Sheet Arrangements

We do not currently engage in off-balance sheet financing arrangements. In addition, we do not have any interest in entities referred to as variable interest entities, which includes special purpose entities and other structured finance entities.

 

Critical Accounting Policies and Estimates

 

Our unaudited condensed consolidated financial statements are prepared in accordance with U.SU.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical experience and on various other assumptions that we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

 

Our significant accounting policies are more fully described in Note 2 to the audited consolidated financial statements included in our Annual Report filed on Form 10-K for the year ended December 31, 2021.2022. We believe that the assumptions and estimates associated with stock-based compensation, goodwill impairment,revenue recognition, long-term receivables, allowance for doubtful accounts, revenue recognition,expected credit losses, warranty accrual, for severance and income taxesstock-based compensation have the most significant impact on our unaudited condensed consolidated financial statements, and therefore, we consider these to be our critical accounting policies and estimates.

 

Revenue Recognition

 

We generate revenue from (1) sales of systems through our subscription model, traditional system sales to customers and distributors, (2) other product revenues from the sale of ARTAS procedure kits, marketing supplies and kits, consumables and (3) service revenue from the sale ofand our extended warranty service contracts provided to existing customers and VeroGrafters technician services. VeroGrafters technician services were discontinued in the fourth quarter of 2021.customers.

 

We recognize revenues on other products and services in accordance with ASC 606. Revenue is recognized based on the following five steps: (1) identification of the contract(s) with the customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the separate performance obligations in the contract; and (5) recognition of revenue when (or as) the entity satisfies a performance obligation.

 

We record our revenue net of sales tax and shipping and handling costs.

 

Long-term receivables

 

Long-term receivables relate to revenue from our subscription agreementsrevenue or other contracts which stipulate payment terms exceedingwhich exceed one year. They are comprised of the unpaid principal balance, net of the allowance for doubtful accounts.expected credit losses. These receivables have been discounted based on the implicit interest rate in the subscription lease of 9.7%which range between 8% and 10% for the ninesix months ended SeptemberJune 30, 20222023 and a range of between 8% to 9% for the nine months ended SeptemberJune 30, 2021,2022, respectively. Unearned interest revenue represents the interest-onlyinterest only portion of the respective subscription payments and will be recognized in income over the respective payment term as it is earned.

 

Allowance for doubtful accountsexpected credit losses

 

The allowance for doubtful accountsexpected credit losses is based on our assessment of the collectability of customer accounts and the aging of the related invoices and represents our best estimate of probable credit losses in our existing trade accounts receivable. We regularly review the allowance by considering factors such as historical experience, credit quality, the age of the account receivable balances, and current economic conditions that may affect a customer’s ability to pay.

 

5543

 

Warranty accrual

 

We generally offer warranties for all our systems against defects for up to three years. The warranty period begins upon shipment and we record a liability for accrued warranty costs at the time of sale of a system, which consists of the remaining warranty on systems sold based on historical warranty costs and management’s estimates. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts thereof as necessary. We exercise judgment in estimating expected system warranty costs. If actual system failure rates, freight, material, technical support and labor costs differ from our estimates, we will be required to revise our estimated warranty liability. To date, our warranty reserve has been sufficient to satisfy warranty claims paid.

 

Stock-Based Compensation

 

We account for stock-based compensation costs in accordance with the accounting standards for stock-based compensation, which require that all stock-basedstock based payments to employees be recognized in the unaudited condensed consolidated statements of operations based on their fair values.

 

The fair value of stock options on the grant date is estimated using the Black-Scholes option-pricing model using the single-option approach. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, including the option's expected term and the price volatility of the underlying stock, to determine the fair value of the award. We recognize the expense associated with options using a single-award approach over the requisite service period.

 

Financial statements in U.S. dollars

 

We believe that the U.S. dollar is the currency in the primary economic environment in which we operate. The U.S. dollar is the most significant currency in which our revenues are generated, and our costs are incurred. In addition, our debt and equity financings are generally based in U.S. dollars. Therefore, our functional currency, and that of our subsidiaries, is the U.S. dollar.

 

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances are re-measuredremeasured into U.S. dollars in accordance with the principles set forth in ASC 830-10 “Foreign Currency Translation”. All exchange gains and losses from re-measurement of monetary balance sheet items resulting from transactions in non-U.S. dollar currencies are recorded as foreign exchange loss (income) in the unaudited condensed consolidated statement of operations as they arise.

 

JOBS Act Accounting Election

We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our unaudited condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Recent Accounting Pronouncements

 

See Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for recently issued accounting pronouncements not yet adopted as of the date of this Quarterly Report on Form 10-Q.

 

5644

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide disclosure for this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of disclosure controls and procedures

 

As of SeptemberJune 30, 2022,2023, our management, under the supervision of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of SeptemberJune 30, 2022.2023.

 

We have performed an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control-Integrated Framework. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our internal controls over financial reporting were effective as of SeptemberJune 30, 2022.2023.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of these limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become ineffective because of changes in conditions or that the degree of compliance with established policies or procedures may deteriorate.

 

Changes in Internal Control over Financial Reporting

 

There were no material changes in our internal control over financial reporting during the three and ninesix months ended SeptemberJune 30, 20222023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

This Quarterly Report on Form 10-Q does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for “emerging growth companies.”

 

5745

 

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

In the ordinary course of our operations, we become involved in routine litigation incidental to the business. Material proceedings are described under Note 8,9, “Commitments and Contingencies” to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

 

ITEM 1A. RISK FACTORS

 

Our operations and financial results are subject to various risk and uncertainties, including those described below and the risk factors described under Part I, Item 1A. Risk Factors in our latest Form 10-K for the year ended December 31, 2021 and our Form 10-Q for the quarter ended March 31, 2022 and June 30, 2022, any of which could adversely affect our business, results of operations, financial condition and prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider the risks described below and the other information in this Quarterly Report on Form 10-Q, our unaudited condensed consolidated financial statements, and the related notes thereto, and Managements Discussion and Analysis of Financial Condition and Results of Operations, included herein, and the risk factors previously disclosed in Part I, Item 1A. Risk Factors in our Form 10-K for the year ended December 31, 20212022 and our Form 10-Q for the quarter ended March 31, 2022 and June 30, 2022 filed with the SEC and incorporated by reference herein.

 

Our subscription-based model exposes usWe offer credit terms to the credit risk of oursome qualified customers over the life of the subscription agreement.and distributors. In the event that our customers faila customer or distributor defaults on the amounts payable to make the monthly payments under their subscription agreements,us, our financial results may be adversely affected.

 

For the ninesix months ended SeptemberJune 30, 2023 and 2022, approximately 30% and 2021, approximately 47% and 56%49% of our total system revenues were derived from our subscription-based model. Although the ARTAS System is not available underUnder our subscription-basedsubscription model, we expect our subscription-based business model to continue to represent a significant portion of our revenue for the foreseeable future. We collect an up-front fee, combined with a monthly payment schedule typically over a period of 36 months, with approximately 40% to 45% of total contract payments collected in the first year. For accounting purposes, these arrangements are considered to be sales-type finance leases, where the present value of all cash flows to be received under the subscription agreement is recognized as revenue upon shipment of the system to the customer. As part of our sales and marketing effort, we do not generally require our customers to undergo a formal credit check as is typically required with third-party equipment lease financing. Instead, to ensure that each monthly installment is made on time and that the customer’s systems are serviced in accordance with the terms of the warranty, every system requires a monthly activation code, which we provide to the customer upon receiving each monthly installment. If a customer does not make timely payment of a monthly installment, the customer will not receive an activation code and will be unable to use the system. Because this process does not protect us from the economic impact of a customer’s failure to make its monthly payments, we normally maintain a purchase money security interest over the devices sold under a subscription agreement and therefore enjoy priority as a secured creditor, entitling us to certain rights in the event of a customer default or bankruptcy. We cannot provide any assurance that the financial position of customers purchasing products and services under a subscription agreement will not change adversely before we receive all the monthly installment payments due under the contract. As a result of the global economic turmoil that has resulted from COVID-19, many of our customers experienced difficulty in making timely payments, or payments at all, during the pandemic which had resulted in higher than anticipated bad debt expense over the course of the 2020 and 2021 fiscal years. Despite the improvement we have seen in our collection experience over the last year and for the nine months ended September 30, 2022, we cannot assure you that our customers will continue payments under their agreements or that we will not experience customer defaults even after local economies reopen for business. In the event that there is a default by any of the customers to whom we have sold systems under the subscription-based model, we may recognize bad debt expenses in our general and administrative expenses. If the extent of such defaults is material, it could negatively affect our results of operations and operating cash flows.

 

58

30 to 90 days to qualified customers and distributors. In the event that there is a default by any of the customers or distributors to whom we have provided credit terms, we may recognize bad debt expenses in our general and administrative expenses. If the extent of such defaults is material, it could negatively affect our future results of operations and cash flows.

 

Global supply chain disruptionWe may also be adversely affected by bankruptcies or other business failures of our customers, distributors, and inflationpotential customers. A significant delay in the collection of accounts receivable or a reduction of accounts receivables collected may have a material adverse effect on the Company's business, financial condition and results of operations.impact our liquidity or result in bad debt expenses.


Global supply chain disruption and inflation may have a material adverse effect on the Company's business, financial condition and results of operations. The Company maintains manufacturing operations at its facilities in San Jose, California and Yokneam, Israel.

We depend on third-party suppliers and manufacturers to produce components and provide raw materials used to manufacture our products. The disruptions to the global economy in 2020 and 2021 impeded global supply chains and resulted in longer lead times and increased component costs and freight expenses. As a result, our suppliers or manufacturers may not have the materials, capacity, or capability to timely manufacture our products and alternative suppliers or manufacturers may not be readily available or cost efficient, which would negatively affect our results of operations. Despite the actions the Company has undertaken to minimize the impacts from disruptions to the global economy, there can be no assurances that unforeseen future events in the global supply chain, and inflationary pressures, will not have a material adverse effect on its business, financial condition, and results of operations.

If we fail to meet the requirements for continued listing on the Nasdaq Global Select Market, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital.

Our common stock is currently listed for quotation on the Nasdaq Global Market. We are required to meet specified requirements in orderable to maintain our listing on The Nasdaq Capital Market and it may become more difficult to sell our stock in the Nasdaq Global Market, including, among other things, a minimum bid price of $1.00 per share (the “Minimum Bid Price”)public market.

On June 13, 2022,May 31, 2023, we received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying stating that our stockholders’ equity as reported in our Quarterly Report on Form 10-Q for the period ended March 31, 2023 was below the minimum $2,500,000 required for continued listing under Listing Rule 5550(b)(1) (“Minimum Equity Requirement”).

The Notice had no immediate effect on the listing of our common stock.

On July 17, 2023, we submitted to Nasdaq a plan to regain compliance with the Minimum Equity Requirement (the "Plan"). On July 28, 2023, Nasdaq granted us an extension until November 27, 2023 (the "Extension") to evidence compliance with the Minimum Equity Requirement, conditioned upon our achievement of certain milestones as set forth in the Plan.

Despite Nasdaq's grant of the Extension, there can be no assurance that for 30 consecutive business days,we will be able to achieve the bid price forrequired milestones in the Plan or evidence compliance with the Minimum Equity Requirement within the timeframe required by Nasdaq, or that we will be able to maintain compliance with the other Nasdaq Listing Rules. If we are unable to timely regain compliance with the Minimum Equity Requirement, or if we fall out of compliance with one or more of the other Nasdaq Listing Rules, Nasdaq could seek to delist our common stock, was belowin which case we would have the Minimum Bid Price requiredright to maintain continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1), (the “Minimum Bid Requirement”). We have 180 days to regain compliance by maintaining the Minimum Bid Price for a minimum of ten consecutive business days before December 12, 2022, at which time the Staff will provide written notification to the Company that it complies with the Minimum Bid Requirement, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(G).

appeal such determination. If we fail to satisfy the Nasdaq Global Market’s continued listing requirements, including the Minimum Bid Requirement, we may transfer to the Nasdaq Capital Market, which generally has lower financial requirements for initial listing, to avoid delisting, or, if we fail to meet its listing requirements, the OTC Bulletin Board. A transfer of our listing to the Nasdaq Capital Market or having our common stock trade on the OTC Bulletin Boardultimately is delisted, our shareholders could adversely affect the liquidity of our common stock. Any such event could make it more difficult to dispose of, or obtain accurate quotations for the price of, our common stock, and there also would likely be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further. We may also face othersignificant adverse consequences, in such event, such as negative publicity, a decreased ability to obtain additional financing, diminished investor and/or employee confidence, and the lossincluding:

Limited availability or market quotations for our common stock;

Reduced liquidity of our common stock;

Determination that shares of our common stock are “penny stock”, which would require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock;

Limited amount of news an analysts’ coverage of us; and

Decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.

46

 


 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Unregistered Sales of Equity Securities

 

ThereExcept as otherwise disclosed in the Company’s Current Report on Form 8-K filed with the SEC on May 15, 2023, there were no unregistered securities issued and sold during the three and ninesix months ended SeptemberJune 30, 2022.2023.

 

Use of Proceeds

 

None

 

Issuer Purchases of Equity Securities

 

None.

 

5947

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

Exhibit

Number

Description

Form

Date

Number

 

Filed

Herewith

       

3.1

Amended and Restated Certificate of Incorporation of Restoration Robotics, Inc.

8-K

10-17-17

3.1

  
       

3.2

Certificate of Amendment of Certificate of Incorporation of Restoration Robotics, Inc.

8-K

11-7-19

3.1

  
       

3.3

Second Amended and Restated Bylaws of Venus Concept Inc.

8-K

11-7-19

3.2

  
       
10.1Employment Agreement, dated October 2, 2022, between Rajiv De Silva and Venus Concept Inc.8-K10-3-22

10.1

  
       
10.2Employment Agreement, dated October 6, 2022, between Hemanth Varghese and Venus Concept Canada Corp.8-K10-11-2210.1  
       

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.

    

X

       

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.

    

X

       

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    

X

       

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    

X

       

101.INS

Inline XBRL Instance Document

    

X

       

101.SCH

Inline XBRL Taxonomy Extension Schema Document

    

X

       

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

    

X

       

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

    

X

       

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

    

X

       

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

    

X

       

        104

Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)  

 

 

X

Exhibit

Number

Description

Form

Date

Number

  

Filed

Herewith

        

3.1

Amended and Restated Certificate of Incorporation of Restoration Robotics, Inc.

8-K

10-17-17

3.1

   
        

3.2

Certificate of Amendment of Certificate of Incorporation of Restoration Robotics, Inc.

8-K

11-7-19

3.1

   
        
3.3Certificate of Amendment of Certificate of Incorporation of Venus Concept Inc.8-K5-11-23

3.1

   
        
3.4Certificate of Amendment of Certificate of Incorporation of Venus Concept Inc.8-K6-26-23

3.1

   
        

3.5

Second Amended and Restated Bylaws of Venus Concept Inc.

8-K

11-7-19

3.2

   
        

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

X

        

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

     

X

        

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

X

        

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     

X

        

101.INS

Inline XBRL Instance Document

     

X

        

101.SCH

Inline XBRL Taxonomy Extension Schema Document

     

X

        

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

     

X

        

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

     

X

        

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

     

X

        

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

     

X

        

        104

Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)  

 

 

 

X

 

*         The certification attached as Exhibit 32.1 and Exhibit 32.2 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the United States Securities and Exchange Commission and is not to be incorporated by reference into any filing of Venus Concept Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

 

6048

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Venus Concept Inc.

 

 

 

 

Date: November 10, 2022August 14, 2023

 

By:

/s/ Rajiv De Silva

 

 

 

Rajiv De Silva

 

 

 

Chief Executive Officer

 

 

 

 

Date: November 10, 2022

August 14, 2023

 

By:

/s/ Domenic Della Penna

 

 

 

Domenic Della Penna

 

 

 

Chief Financial Officer

 

6149